EP2704749A1 - Conjugués peptides/oligonucléotides - Google Patents

Conjugués peptides/oligonucléotides

Info

Publication number
EP2704749A1
EP2704749A1 EP11793913.2A EP11793913A EP2704749A1 EP 2704749 A1 EP2704749 A1 EP 2704749A1 EP 11793913 A EP11793913 A EP 11793913A EP 2704749 A1 EP2704749 A1 EP 2704749A1
Authority
EP
European Patent Office
Prior art keywords
conjugate
occurrence
alkyl
independently
carrier peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP11793913.2A
Other languages
German (de)
English (en)
Inventor
Gunnar J. Hanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/101,942 external-priority patent/US20110269665A1/en
Priority claimed from US13/107,528 external-priority patent/US9238042B2/en
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Publication of EP2704749A1 publication Critical patent/EP2704749A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A61K47/6455—Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Definitions

  • the present invention is generally related to oligonucleotide compounds (oligomers) useful as antisense compounds, and more particularly to oligomer compounds conjugated to cell-penetrating peptides, and the use of such oligomer compounds in antisense applications.
  • oligomers oligonucleotide compounds
  • Tat 49 57 A segment of the HIV Tat protein consisting of amino acid residues 49- 57 (Tat 49 57, having the sequence RKKRRQRRR) has been used to deliver biologically active peptides and proteins to cells (e.g. Barsoum et al, 1994, PCT Pubn. No. WO 94/04686). Tat (49 60) has been used to enhance delivery of phosphorothioate oligonucleotides (Astriab-Fisher, Sergueev et al. 2000; Astriab-Fisher, Sergueev et al. 2002).
  • Reverse Tat or rTat(57-49) (RRRQRRKKR)
  • RRRQRRKKR Reverse Tat, or rTat(57-49)
  • Rothbard and Wender have also disclosed other arginine-rich transport polymers (PCT Pubn. No. WO 01/62297; U.S. Patent No. 6,306,993; US Patent Appn. Pubn. No. 2003/0032593).
  • Oligonucleotides are one class of potentially useful drug compounds whose delivery has often been an impediment to therapeutic use.
  • Phosphorodiamidate- linked morpholino oligomers (PMOs; see e.g. Summerton and Weller, 1997) have been found more promising in this regard than charged oligonucleotide analogs such as phosphorothioates.
  • the PMOs are water-soluble, uncharged or substantially uncharged antisense molecules that inhibit gene expression by preventing binding or progression of splicing or translational machinery components.
  • PMOs have also been to shown to inhibit or block viral replication (Stein, Skilling et al. 2001; McCaffrey, Meuse et al. 2003). They are highly resistant to enzymatic digestion (Hudziak, Barofsky et al.
  • PMOs have demonstrated high antisense specificity and efficacy in vitro in cell- free and cell culture models (Stein, Foster et al. 1997; Summerton and Weller 1997), and in vivo in zebrafish, frog and sea urchin embryos (Heasman, Kofron et al. 2000; Nasevicius and Ekker 2000), as well as in adult animal models, such as rats, mice, rabbits, dogs, and pigs (see e.g. Arora and Iversen 2000; Qin, Taylor et al. 2000;
  • Antisense PMO oligomers have been shown to be taken up into cells and to be more consistently effective in vivo, with fewer nonspecific effects, than other widely used antisense oligonucleotides (see e.g. P. Iversen, "Phosphoramidite
  • improved antisense or antigene performance includes; lower toxicity, stronger affinity for DNA and RNA without compromising sequence selectivity; improved pharmacokinetics and tissue distribution; improved cellular delivery and reliable and controllable in vivo distribution.
  • the disclosed conjugates have decreased toxicity and/or enhanced cell delivery, potency, and/or tissue distribution compared to other oligonucleotide analogues and/or can be more effectively delivered to the target organs.
  • These superior properties give rise to favorable therapeutic indices, reduced clinical dosing, and lower cost of goods.
  • the present disclosure provides a conjugate comprising:
  • nucleic acid analogue comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid
  • the carrier peptide comprises a glycine (G) or proline (P) amino acid at a carboxy terminus of the carrier peptide, and the carrier peptide is covalently attached to the nucleic acid analogue.
  • G glycine
  • P proline
  • a composition comprising the above conjugate and a pharmaceutically acceptable vehicle are also provided.
  • the present disclosure provides a method of inhibiting production of a protein, the method comprising exposing a nucleic acid encoding the protein to a conjugate of the present disclosure.
  • Another aspect of the present disclosure includes a method for enhancing the transport of a nucleic acid analogue into a cell, the method comprising conjugating the carrier peptide of claim 1 to a nucleic acid analogue, and wherein the transport of the nucleic acid analogue into the cell is enhanced relative to the nucleic acid analogue in unconjugated form.
  • the disclosure is directed to a method of treating a disease in a subject, the method comprising administering a therapeutically effective amount of a disclosed conjugate to the subject.
  • Methods of making the conjugates, methods for their use and carrier peptides useful for conjugating to nucleic acid analogues are also provided.
  • Figure 1 A shows an exemplary morpholino oligomer structure comprising a phosphorodiamidate linkage.
  • Figure IB shows a morpholino oligomer conjugated to a carrier peptide at the 5 ' end.
  • Figure 1C shows a morpholino oligomer conjugated to a carrier peptide at the 3 ' end.
  • Figures 1D-G show the repeating subunit segment of exemplary morpholino oligonucleotides, designated ID through 1G.
  • Figure 2 depicts exemplary intersubunit linkages linked to a morpholino
  • Figure 3 is a reaction scheme showing preparation of a linker for solid- phase synthesis.
  • Figure 4 demonstrates preparation of a solid support for oligomer synthesis.
  • Figures 5A, 5B and 5C show exon skipping data for exemplary conjugates compared to a known conjugate in mouse quadriceps, diaphragm and heart, respectively.
  • Figures 6A, 6B and 6C are alternate representations of exon skipping data for exemplary conjugates compared to a known conjugate in mouse quadriceps, diaphragm and heart, respectively.
  • Figures 7A and 7B are graphs depicting blood urea nitrogen (BUN) levels and survival rate of mice treated with various peptide -oligomer conjugates, respectively.
  • FIGS 8A and 8B show kidney injury marker (KIM) data and Clusterin (Clu) data for mice treated with various peptide-oligomer conjugates, respectively.
  • Figures 9A, 9B, 9C and 9D are graphs comparing the exon skipping, BUN levels, precent survival and KIM levels, respectively, in mice treated with an exemplary conjugate compared to a known conjugate.
  • Figure 10 presents KIM data for mice treated with various conjugates.
  • FIG 11 shows results of BUN analysis of mice treated with various conjugates.
  • Figure 12 is a graph showing the concentration of various oligomers in mouse kidney tissue.
  • Amino refers to the -NH 2 radical.
  • Hydroxy or "hydroxyl” refers to the -OH radical.
  • 'Nitro refers to the -N0 2 radical.
  • Deoxycholate refers to the following structure:
  • Alkyls comprising any number of carbon atoms from 1 to 30 are included.
  • An alkyl comprising up to 30 carbon atoms is refered to as a Ci-C 30 alkyl, likewise, for example, an alkyl comprising up to 12 carbon atoms is a C 1 -C 12 alkyl.
  • Alkyls (and other moieties defined herein) comprising other numbers of carbon atoms are represented similarity.
  • Alkyl groups include, but are not limited to, Ci-C 3 o alkyl, C 1 -C 20 alkyl, C 1 -C 15 alkyl, C 1 -C 10 alkyl, Ci-Cs alkyl, Ci-C 6 alkyl, C 1 -C4 alkyl, Ci- C 3 alkyl, Ci-C 2 alkyl, C 2 -C 8 alkyl, C 3 -C 8 alkyl and C 4 -C 8 alkyl.
  • Representative alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, 1-methylethyl
  • an alkyl group may be optionally substituted as described below.
  • Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group. Alkylenes may be saturated or unsaturated (i.e., contains one or more double and/or triple bonds). Representative alkylenes include, but are not limited to, C 1 -C 12 alkylene, Ci-Cg alkylene, Ci-C 6 alkylene, C 1 -C4 alkylene, Ci-C 3 alkylene, C 1 -C 2 alkylene, Ci alkylene.
  • alkylene groups include, but are not limited to, methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single or double bond and to the radical group through a single or double bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
  • an alkylene chain may be optionally substituted as described below.
  • Alkoxy refers to a radical of the formula -OR a where R a is an alkyl radical as defined. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted as described below.
  • Alkoxyalkyl refers to a radical of the formula -R b OR a where R a is an alkyl radical as defined and where Rb is an alkylene radical as defined. Unless stated otherwise specifically in the specification, an alkoxyalkyl group may be optionally substituted as described below.
  • an alkyloxycarbonyl group may be optionally substituted as described below.
  • Alkylamino refers to a radical of the formula -NHR a or -NR a R a where each R a is, independently, an alkyl radical as defined above. Unless stated otherwise specifically in the specification, an alkylamino group may be optionally substituted as described below.
  • Aminoalkyl refers to a radical of the formula -Rb-NRaRa where Rb is an alkylene radical as defined above, and each R a is independently a hydrogen or an alkyl radical.
  • Thioalkyl refers to a radical of the formula -SR a where R a is an alkyl radical as defined above. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.
  • Aryl refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms and at least one aromatic ring.
  • the aryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems.
  • Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as- indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene.
  • Aralkyl refers to a radical of the formula -Rb-R c where Rb is an alkylene chain as defined above and R c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl, trityl and the like. Unless stated otherwise specifically in the specification, an aralkyl group may be optionally substituted.
  • Aryloxy refers to a radical of the formula -OR c where R c is one or more aryl radicals as defined above, for example, phenyl. Unless stated otherwise specifically in the specification, an arylcarbonyl group may be optionally substituted.
  • Cycloalkyl refers to a stable, non-aromatic, monocyclic or polycyclic carbocyclic ring, which may include fused or bridged ring systems, which is saturated or unsaturated, and attached to the rest of the molecule by a single bond.
  • Representative cycloalkyls include, but are not limited to, cycloaklyls having from three to fifteen carbon atoms and from three to eight carbon atoms.
  • Monocyclic cyclcoalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic radicals include, for example, adamantyl, norbornyl, decalinyl, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Unless otherwise stated
  • a cycloalkyl group may be optionally substituted.
  • Cycloalkylalkyl refers to a radical of the formula -R b R d where R b is an alkylene chain as defined above and R d is a cycloalkyl radical as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.
  • fused refers to any ring structure described herein which is fused to an existing ring structure.
  • the fused ring is a heterocyclyl ring or a heteroaryl ring
  • any carbon atom on the existing ring structure which becomes part of the fused heterocyclyl ring or the fused heteroaryl ring may be replaced with a nitrogen atom.
  • guanidinylalkylcarbonyl group may be optionally substituted as described below.
  • Halo or halogen refers to bromo, chloro, fluoro or iodo.
  • Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, e.g., trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1 ,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1 ,2-dibromoethyl, and the like. Unless stated otherwise specifically in the specification, a haloalkyl group may be optionally substituted.
  • Perhalo or “perfluoro” refers to a moiety in which each hydrogen atom has been replaced by a halo atom or fluorine atom, respectively.
  • Heterocyclyl refers to a stable 3- to 24-membered non-aromatic ring radical comprising 2 to 23 carbon atoms and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur.
  • the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated.
  • heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl,
  • Heteroaryl refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous and sulfur, and at least one aromatic ring.
  • the heteroaryl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
  • Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodioxolyl, benzofuranyl, benzooxazolyl,
  • benzothiazolyl benzothiadiazolyl, benzo[3 ⁇ 4][l,4]dioxepinyl, 1 ,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotriazolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl,
  • a heteroaryl group may be optionally substituted.
  • substituted as used herein means any of the above groups (i.e., alkyl, alkylene, alkoxy, alkoxyalkyl, alkylcarbonyl, alkyloxycarbonyl,alkylamino, amidyl,
  • amidinylalkyl amidinylalkyl, amidinylalkylcarbonyl, aminoalkyl, aryl, aralkyl, arylcarbonyl, aryloxycarbonyl, aralkylcarbonyl, aralkyloxycarbonyl, aryloxy, cycloalkyl,
  • cycloalkylalkyl may be further functionalized wherein at least one hydrogen atom is replaced by a bond to a non-hydrogen atom substituent.
  • a substituted group may include one or more substituents selected from: oxo, -C0 2 H, nitrile, nitro, -CONH 2 , hydroxyl, thiooxy, alkyl, alkylene, alkoxy, alkoxyalkyl, alkylcarbonyl, alkyloxycarbonyl, aryl, aralkyl, arylcarbonyl, aryloxycarbonyl, aralkylcarbonyl, aralkyloxycarbonyl, aryloxy, cycloalkyl, cycloalkylalkyl,
  • cycloalkylcarbonyl cycloalkylalkylcarbonyl, cycloalkyloxycarbonyl, heterocyclyl, heteroaryl, dialkylamines, arylamines, alkylarylamines, diarylamines, N-oxides, imides, and enamines; a silicon atom in groups such as trialkylsilyl groups, dialkylarylsilyl groups, alkyldiarylsilyl groups, triarylsilyl groups, perfluoroalkyl or perfluoroalkoxy, for example, trifluoromethyl or trifluoromethoxy.
  • Substituted also means any of the above groups in which one or more hydrogen atoms are replaced by a higher-order bond (e.g., a double- or triple-bond) to a heteroatom such as oxygen in oxo, carbonyl, carboxyl, and ester groups; and nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • a higher-order bond e.g., a double- or triple-bond
  • nitrogen in groups such as imines, oximes, hydrazones, and nitriles.
  • R g and R are the same or different and independently hydrogen, alkyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and/or heteroarylalkyl.
  • each of the foregoing substituents may also be optionally substituted with one or more of the above substituents.
  • any of the above groups may be substituted to include one or more internal oxygen or sulfur atoms.
  • an alkyl group may be substituted with one or more internal oxygen atoms to form an ether or poly ether group. Similarily, an alkyl group may be substituted with one or more internal sulfur atoms to form a thioether, disulfide, etc. Amidyl moieties may be substituted with up to 2 halo atoms, while other groups above may be substituted with one or more halo atoms. Any of the above groups may also be substituted with amino, monoalklyamino, guanidinyl or amidynyl. Optional substitutents for any of the above groups also include arylphosphoryl, for example -R a P(Ar) 3 wherein R a is an alkylene and Ar is aryl moiety, for example phenyl.
  • antisense oligomer or “antisense compound” are used interchangeably and refer to a sequence of subunits, each having a base carried on a backbone subunit composed of ribose or other pentose sugar or morpholino group, and where the backbone groups are linked by intersubunit linkages that allow the bases in the compound to hybridize to a target sequence in a nucleic acid (typically an RNA) by Watson-Crick base pairing, to form a nucleic acid:oligomer heteroduplex within the target sequence.
  • the oligomer may have exact sequence complementarity to the target sequence or near complementarity.
  • Such antisense oligomers are designed to block or inhibit translation of the mRNA containing the target sequence, and may be said to be "directed to" a sequence with which it hybridizes.
  • a “morpholino oligomer” or “PMO” refers to a polymeric molecule having a backbone which supports bases capable of hydrogen bonding to typical polynucleotides, wherein the polymer lacks a pentose sugar backbone moiety, and more specifically a ribose backbone linked by phosphodiester bonds which is typical of nucleotides and nucleosides, but instead contains a ring nitrogen with coupling through the ring nitrogen.
  • An exemplary"morpholino" oligomer comprises morpholino subunit structures linked together by (thio)phosphoramidate or (thio)phosphorodiamidate linkages, joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit, each subunit comprising a purine or pyrimidine base-pairing moiety effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide.
  • Morpholino oligomers are detailed, for example, in U.S. Pat. Nos.
  • PMOs include PMOs wherin the intersubunit linkages are linkage (Al).
  • PMO+ refers to phosphorodiamidate morpholino oligomers comprising any number of ( 1 -piperazino)phosphinylideneoxy , ( 1 -(4-(ro-guanidino-alkanoyl))- piperazino)phosphinylideneoxy linkages (A2 and A3) that have been described previously (see e.g., PCT publication WO/2008/036127 which is incorporated herein by reference in its entirety.
  • PMO-X refers to phosphorodiamidate morpholino oligomers disclosed herein comprising at least one (B) linkage or at least one of the disclosed terminal modifications.
  • a "phosphoramidate” group comprises phosphorus having three attached oxygen atoms and one attached nitrogen atom
  • a “phosphorodiamidate” group comprises phosphorus having two attached oxygen atoms and two attached nitrogen atoms.
  • one nitrogen is always pendant to the backbone chain.
  • the second nitrogen, in a phosphorodiamidate linkage, is typically the ring nitrogen in a
  • Thiophosphoramidate or thiophosphorodiamidate linkages are phosphoramidate or phosphorodiamidate linkages, respectively, wherein one oxygen atom, typically the oxygen pendant to the backbone, is replaced with sulfur.
  • Intersubunit linkage refers to the linkage connecting two morpholino subunits, for example structure (I).
  • Charged”, “uncharged”, “cationic” and “anionic” as used herein refer to the predominant state of a chemical moiety at near-neutral pH, e.g., about 6 to 8.
  • the term may refer to the predominant state of the chemical moiety at physiological pH, that is, about 7.4.
  • “Lower alkyl” refers to an alkyl radical of one to six carbon atoms, as exemplified by methyl, ethyl, n-butyl, i-butyl, t-butyl, isoamyl, n-pentyl, and isopentyl.
  • a "lower alkyl” group has one to four carbon atoms.
  • a "lower alkyl” group has one to two carbon atoms; i.e. methyl or ethyl.
  • “lower alkenyl” refers to an alkenyl radical of two to six, preferably three or four, carbon atoms, as exemplified by allyl and butenyl.
  • a “non-interfering" substituent is one that does not adversely affect the ability of an antisense oligomer as described herein to bind to its intended target.
  • substituents include small and/or relatively non-polar groups such as methyl, ethyl, methoxy, ethoxy, or fluoro.
  • An oligonucleotide or antisense oligomer "specifically hybridizes" to a target polynucleotide if the oligomer hybridizes to the target under physiological conditions, with a Tm greater than 37 °C, greater than 45 °C, preferably at least 50 °C, and typically 60 °C-80 °C or higher.
  • Tm The "Tm” of an oligomer is the temperature at which 50% hybridizes to a complementary polynucleotide. Tm is determined under standard conditions in physiological saline, as described, for example, in Miyada et al, Methods Enzymol. 154:94-107 (1987). Such hybridization may occur with “near” or “substantial” complementary of the antisense oligomer to the target sequence, as well as with exact complementarity.
  • Polynucleotides are described as "complementary" to one another when hybridization occurs in an antiparallel configuration between two single-stranded polynucleotides.
  • Complementarity the degree that one polynucleotide is
  • a first sequence is an "antisense sequence" with respect to a second sequence if a polynucleotide whose sequence is the first sequence specifically binds to, or specifically hybridizes with, the second polynucleotide sequence under physiological conditions.
  • targeting sequence is the sequence in the oligonucleotide analog that is complementary (meaning, in addition, substantially complementary) to the target sequence in the RNA genome.
  • the entire sequence, or only a portion, of the analog compound may be complementary to the target sequence.
  • the targeting sequence is formed of contiguous bases in the analog, but may alternatively be formed of non-contiguous sequences that when placed together, e.g., from opposite ends of the analog, constitute sequence that spans the target sequence.
  • the "backbone" of an oligonucleotide analog refers to the structure supporting the base-pairing moieties; e.g., for a morpholino oligomer, as described herein, the "backbone” includes morpholino ring structures connected by intersubunit linkages (e.g., phosphorus- containing linkages).
  • a “substantially uncharged backbone” refers to the backbone of an oligonuceltoide analogue wherein less than 50% of the intersubunit linkages are charged at near-neutral pH.
  • a substantially uncharged backbone may comprise less than 50%, less than 40%>, less than 30%>, less than 20%>, less than 10%>, less than 5% or even 0% intersubunit linkages which are charged at near neutral pH.
  • the substantially uncharged backbone comprises at most one charged (at physiological pH) intersubunit linkage for every four uncharged (at physiological pH) linkages, at most one for every eight or at most one for every sixteen uncharged linkages.
  • the nucleic acid analogs described herein are fully uncharged.
  • Target and targeting sequences are described as “complementary” to one another when hybridization occurs in an antiparallel configuration.
  • a targeting sequence may have “near” or “substantial” complementarity to the target sequence and still function for the purpose of the presently described methods, that is, still be “complementary.”
  • the oligonucleotide analog compounds employed in the presently described methods have at most one mismatch with the target sequence per every 10 nucleotides, and preferably at most one mismatch out of 20.
  • the antisense oligomers employed have at least80%>, at least 90%> sequence homology or at least 95% sequence homology, with the exemplary targeting sequences as designated herein.
  • a guanine base may be complementary to either a cytosineor uracil RNA base.
  • heteroduplex refers to a duplex between an oligonculeotide analog and the complementary portion of a target RNA.
  • a “nuclease-resistant heteroduplex” refers to a heteroduplex formed by the binding of an antisense oligomer to its complementary target, such that the heteroduplex is substantially resistant to in vivo degradation by intracellular and extracellular nucleases, such as RNAse H, which are capable of cutting double-stranded RNA/RNA or RNA/DNA complexes.
  • agent is "actively taken up by mammalian cells” when the agent can enter the cell by a mechanism other than passive diffusion across the cell membrane.
  • the agent may be transported, for example, by "active transport”, referring to transport of agents across a mammalian cell membrane by e.g. an ATP-dependent transport mechanism, or by "facilitated transport”, referring to transport of antisense agents across the cell membrane by a transport mechanism that requires binding of the agent to a transport protein, which then facilitates passage of the bound agent across the membrane.
  • modulating expression and/or “antisense activity” refer to the ability of an antisense oligomer to either enhance or, more typically, reduce the expression of a given protein, by interfering with the expression or translation of RNA.
  • the antisense oligomer may directly block expression of a given gene, or contribute to the accelerated breakdown of the RNA transcribed from that gene. Morpholino oligomers as described herein are believed to act via the former (steric blocking) mechanism.
  • Preferred antisense targets for steric blocking oligomers include the ATG start codon region, splice sites, regions closely adjacent to splice sites, and 5 '-untranslated region of mRNA, although other regions have been successfully targeted using morpholino oligomers.
  • amino acid subunit is generally an a-amino acid residue (-CO- CHR-NH-); but may also be a ⁇ - or other amino acid residue (e.g. -CO-CH 2 CHR-NH-), where R is an amino acid side chain.
  • naturally occurring amino acid refers to an amino acid present in proteins found in nature.
  • non-natural amino acids refers to those amino acids not present in proteins found in nature; examples include beta-alanine ( ⁇ - Ala) and 6-aminohexanoic acid (Ahx).
  • an “effective amount” or “therapeutically effective amount” refers to an amount of antisense oligomer administered to a mammalian subject, either as a single dose or as part of a series of doses, which is effective to produce a desired therapeutic effect, typically by inhibiting translation of a selected target nucleic acid sequence.
  • Treatment of an individual (e.g. a mammal, such as a human) or a cell is any type of intervention used in an attempt to alter the natural course of the individual or cell. Treatment includes, but is not limited to, administration of a pharmaceutical composition, and may be performed either prophylactically or subsequent to the initiation of a pathologic event or contact with an etiologic agent. II. Carrier Peptides
  • the present disclosure is directed to conjugates of carrier peptides and nucleic acid analogues.
  • the carrier peptides are generally effective to enhance cell penetration of the nucleic acid analogues.
  • Applicants have surprisingly discovered that including a glycine (G) or proline (P) amino acid subunit between the nucleic acid analogue and the remainder of the carrier peptide (e.g., at the carboxy or amino terminus of the carrier peptide) reduces the toxicity of the conjugate, while the efficacy remains the same or is improved relative to conjugates with different linkages between the carrierpeptide and nucleic acid analogue.
  • the presently disclosed conjugates have a better therapeutic window and are more promising drug candidates than other peptide-oligomer conjugates.
  • glycine is inexpensive and is easily coupled to the nucleic acid analogue (or optional linker) without any possibility of racemization.
  • proline is easily coupled without racemization and also provides carrier peptides which are not helix formers.
  • the hydrophobicity of proline may also confer certain advantages with respect to interaction of the carrier peptide with the lipid bilayer of cells, and carrier peptides comprising multiple prolines (for example in certain embodiments) may resist G-tetraplex formation.
  • the proline moiety when the proline moiety is adjacent to an arginine amino acid subunit, confers metabolic to the conjugates since the argine-proline amide bond is not cleavable by common endopeptidases.
  • conjugates comprising carrier peptides linked to nucleic acid analogues via a glycine or proline amino acid subunit have lower toxicity and similar efficacy compared to other known conjugates.
  • kidney toxicity markers are much lower with the presently disclosed conjugates compared to other conjugates (see e.g., kidney injury marker (KIM) and blood urea nitrogen (BUN) data described inExample 30).
  • the present inventors believe the reduced toxicity of the disclosed conjugates may be related to the absence of unnatural amino acids such as aminohexanoic acid or ⁇ -alanine in the portion of the peptide which is attached to the nucleic acid analogue (e.g., the carboxy terminus). Since these unnatural amino acids are not cleaved in vivo, it is believed that toxic concentrations of the uncleaved peptides may accumulate and cause toxic effects.
  • unnatural amino acids such as aminohexanoic acid or ⁇ -alanine
  • the glycine or proline moiety may be at either the amino or carboxy terminus of the carrier peptide, and in some instances, the carrier peptide may be linked to the nucleic acid analogue directly via the glycine or proline subunit or the carrier peptide may be linked to the nucleic acid analogue via an optional linker.
  • the present disclosure is directed to a conjugate comprising:
  • nucleic acid analogue comprising a substantially uncharged backbone and a targeting base sequence for sequence-specific binding to a target nucleic acid
  • the carrier peptide comprises a glycine (G) or proline (P) amino acid subunit at a carboxy terminus of the carrier peptide and the carrier peptide is covalently attached to the nucleic acid analogue.
  • the carrier peptide comprises a glycine amino acid subunit at the carboxy terminus.
  • the carrier peptide comprises a proline amino acid subunit at the carboxy terminus.
  • the carrier peptide comprises a single glycine or proline at the carboxy terminus (i.e., does not comprise a glycine or proline dimmer or trimer, etc. at the carboxy terminus).
  • the carrier peptide when conjugated to an antisense oligomer having a substantially uncharged backbone, is effective to enhance the binding of the antisense oligomer to its target sequence, relative to the antisense oligomer in unconjugated form, as evidenced by: (i) a decrease in expression of an encoded protein, relative to that provided by the unconjugated oligomer, when binding of the antisense oligomer to its target sequence is effective to block a translation start codon for the encoded protein, or
  • conjugation of the peptide provides this activity in a cell-free translation assay, as described herein.
  • activity is enhanced by a factor of at least two, a factor of at least five or a factor of at least ten.
  • the carrier peptide is effective to enhance the transport of the nucleic acid analog into a cell, relative to the analog in unconjugated form.
  • transport is enhanced by a factor of at least two, a factor of at least two, a factor of at least five or a factor of at least ten.
  • the carrier peptide is effective to decrease the toxicity (i.e., increase maximum tolerated dose) of the conjugate, relative to a conjugate comprising a carrier peptide lacking the terminal glycine or proline amino subunits. In certain embodiments, toxicity is decreased by a factor of at least two, a factor of at least two, a factor of at least five or a factor of at least ten.
  • a further benefit of the peptide transport moiety is its expected ability to stabilize a duplex between an antisense oligomer and its target nucleic acid sequence. While not wishing to be bound by theory, this ability to stabilize a duplex may result from the electrostatic interaction between the positively charged transport moiety and the negatively charged nucleic acid.
  • the length of the carrier peptide is not particularly limited and varies in different embodiments.
  • the carrier peptide comprises from 4 to 40 amino acid subunits.
  • the carrier peptide comprises from 6 to 30, from 6 to 20, from 8 to 25 or from 10 to 20 amino acid subunits.
  • the carrier peptide is straight, while in other embodiments it is branched.
  • the carrier peptides are rich in positively charged amino acid subunits, for example arginine amino acid subunits.
  • a carrier peptide is "rich" in positively charged amino acids if at least 10% of the amino acid subunits are positively charged. For example, in some embodiments at least 20%, at least 30%>, at least 40%, at least 50%, at least 60%, at least 70%, at least 80% or at least 90% of the amino acid subunits are positively charged. In even other embodiments, all the amino acid subunits, except the glycine or proline amino acid subunit, are positively charged. In still other embodiment, all of the positively charged amino acid subunits are arginine.
  • the number of positively charged amino acid subunits in the carrier peptide ranges from 1 to 20, for example from 1 to 10 or from 1 to 6. In certain embodiments, the number of positively charged amino acids in the carrier peptide is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20.
  • the positively charged amino acids can be naturally occurring, non- naturally occurring, synthetic, modified or analogues of naturally occurring amino acids.
  • modified amino acids with a net positive charge may be
  • the positively charged amino acids are histidine (H), lysine (K) or arginine (R).
  • the carrier peptide comprises only natural amino acid subunits (i.e., does not contain unnatural amino acids).
  • the terminal amino acids may be capped, for example with an acetyl, benzoyl or stearyl moiety, for example on the N-terminal end.
  • any number, combination and/or sequence of H, K and/or R may be present in the carrier peptide.
  • all of the amino acid subunits, except the carboxy terminal glycine or proline are positively charged amino acids.
  • at least one of the positively charged amino acids is arginine.
  • all of the positively charged amino acids are arginine, and in even other embodiments the carrier peptide consists of arginine and the carboxy terminal glycine or proline.
  • the carrier peptide comprises no more than seven contiguous arginines, for example no more than six contiguous arginines.
  • the positively charged amino acids is an arginine analog.
  • the carrier peptides may comprise any number of these arginine analogues.
  • the positively charged amino acids may occur in any sequence within the carrier peptide.
  • the positively charged amino acids may alternate or may be sequential.
  • the carrier peptide may comprise the sequence (R d ) m , wherein R d is independently, at each occurrence, a positively charged amino acid and m is an integer ranging from 2 to 12, from 2 to 10, from 2 to 8 or from 2 to 6.
  • R d is arginine
  • the carrier peptide comprises a sequence selected from (R) 4 , (R) 5 , (R) 6 , (R) 7 and (R)g, or selected from (R) 4 , (R) 5 , (R) 6 and (R) 7 for example in specific embodiments the carrier peptide comprises the sequence (R) 6 , for example (R) 6 G or (R) 6 P.
  • the carrier peptide consists of the sequence (R d ) m and the carboxy terminal glycine or proline, wherein R d is independently, at each occurrence, a positively charged amino acid and m is an integer ranging from 2 to 12, from 2 to 10, from 2 to 8 or from 2 to 6.
  • Rd is independently, at each occurrence, arginine, histidine or lysine.
  • R d is arginine
  • the carrier peptide consists of a sequence selected from (R) 4 , (R) 5 ,
  • the carrier peptide consists of the sequence (R) 6 G or (R) 6 P.
  • the carrier peptide may comprise one or more hydrophobic amino acid subunits, the hydrophobic amino acid subunits comprising a substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl or aralkyl side chain wherein the alkyl, alkenyl and alkynyl side chain includes at most one heteroatom for every six carbon atoms acid.
  • the hydrophobic amino acid is phenylalanine (F).
  • the carrier peptide may comprise two or more contingous hydrophobic amino acids such as phenylalanine (F), for example two contiguous phenylalanine moieties.
  • the hydrophobic amino acid(s) may be at any point in the carrier peptide sequence.
  • the carrier peptide comprises the sequence
  • R d is independently, at each occurrence, a positively charged amino acid
  • x and y are independently, at each occurrence, 0 or 1, provided that x + y is 1 or 2
  • z is 1, 2, 3, 4, 5 or 6
  • Y b is -C(0)-(CHR e ) n -NH-
  • n is 2 to 7 and each R e is independently, at each occurrence, hydrogen or methyl.
  • R d is independently, at each occurrence arginine, histidine or lysine.
  • each R d is arginine.
  • n is 5 and Y b is an aminohexanoic acid moiety.
  • n is 2 and Y b is a ⁇ -alanine moiety.
  • R e is hydrogen.
  • x is 1 and y is 0, and the carrier peptide comprises the sequence (R d Y b R d ) z .
  • n is 5 and Y b is an aminohexanoic acid moiety.
  • n is 2 and Y b is a ⁇ -alanine moiety.
  • R e is hydrogen.
  • x is 0 and y is 1
  • the carrier peptide comprises the sequence (R d R d Y b ) z .
  • n is 5 and Y b is an aminohexanoic acid moiety.
  • n is 2 and Y b is a ⁇ -alanine moiety.
  • R e is hydrogen.
  • the carrier peptide comprises the sequence
  • R d Y b (R d Y b ) p , wherein R d and Y b are as defined above and p is an integer ranging from 2 to 8.
  • each R d is arginine.
  • n is 5 and Y b is an aminohexanoic acid moiety.
  • n is 2 and Y b is a ⁇ -alanine moiety.
  • R e is hydrogen.
  • the carrier peptide comprises the sequence
  • the peptides may comprise the ILFQY sequence in addition to any of the other sequences disclosed herein.
  • the carrier peptide may comprise ILFQY and [(R d Y b R d ) x (R d R d Y b ) y ] z , [(R d R d Y b ) y (R d Y b R d ) x ] z , (R d Y b ) p or combinations thereof wherein R d , x, y and Y b are as defined above.
  • the [(R d Y b R d ) x (R d R d Y b ) y ] z , [(R d R d Y b ) y (R d Y b R d ) x ] z or (R d Y b ) p sequence may be on the amino terminus, carboxy terminus or both of the ILFQY sequence.
  • x is 1 and y is 0 and the carrier peptide comprises (R d Y b R d ) z linked to the ILFQY sequence via an optional Z linker.
  • the carrier peptide comprises the sequence ILFQ, IWFQ or ILIQ.
  • Other embodiments include carrier peptides which comprise the sequence PPMWS, PPMWT, PPMFS or PPMYS.
  • the carrier peptide may comprise these sequences in addition to any of the other sequences described herein, for example in addition to the sequences [(R d Y b R d ) x (R d R d Y b ) y z , [(R d R d Y b ) y (R d Y b R d ) x ] z or (R d Y b ) p wherein R d , x, y and Y b are as defined above.
  • the carrier peptide include modifications to naturally occurring amino acid subunits, for example the amino terminal or carboxy terminal amino acid subunit may be modified. Such modifications include capping the free amino or free carboxy with a hydrophobic group.
  • the amino terminus may be capped with an acetyl, benzoyl or stearoyl moiety.
  • any of the pepetide sequences in Table 1 may have such modifications even if not specifically depticted in the table.
  • the amino terminus of the carrier peptide can be depicted as follows:
  • the carrier peptide comprises at least one of alanine, asparagine, cysteine, glutamine, glycine, histidine, lysine, methionine, serine or threonine.
  • the carrier peptide consists of the noted sequences and the carboxy terminal glycine or proline amino acid subunit.
  • the carrier peptide does not consist of the following sequences (amino terminal to carboxy terminal): R ⁇ G, R 7 G, RgG, R 5 GR 4 G, R 5 F 2 R 4 G, Tat-G, rTat-G, (RXR 2 G 2 ) 2 or (RXR 3 X) 2 G.
  • the carrier peptide does not consist of RgG, R 9 G or R 9 F 2 G.
  • the carrier peptide does not consist of the following sequences: Tat-G, rTat-G, RgF 2 G, R 5 F 2 R4, R 4 G, R 5 G, RgG, R 7 G, R 8 G, R 9 G, (RXR) 4 G, (RXR) 5 G, (RXRRBR) 2 G, (RAR) 4 F 2 or (RGR) 4 F 2 .
  • the carrier peptide does not consist of "Penetratin" or "RePen".
  • the present disclosure provides a peptide -nucleic acid analog conjugate, comprising
  • nucleic acid analog having a substantially uncharged backbone and a targeting base sequence
  • a peptide comprising a carboxy terminal glycine or proiline amino acid subunit and consisting of 8 to 16 additional other subunits selected from R d subunits, Y subunits, and optional Z subunits, including at least eight R d subunits, at least two Y subunits, and at most three Z subunits, where >50% of said subunits are R d subunits, and where
  • the at least two Y subunits are Y a or Y b , wherein:
  • each Y a is independently a neutral a-amino acid subunits having side chains independently selected from substituted or unsubstituted alkyl, alkenyl, alkynyl, aryl, and aralkyl, wherein said side chain, when selected from substituted alkyl, alkenyl, and alkynyl, includes at most one heteroatom for every two, preferably every four, and more preferably every six carbon atoms, and wherein said subunits are contiguous or are flanking a linker moiety, and
  • n 2 to 7 and each R e is independently, at each occurrence, hydrogen or methyl.
  • Z represents an amino acid subunit selected from alanine, asparagine, cysteine, glutamine, glycine, histidine, lysine, methionine, serine, threonine and amino acids having side chains which are one- or two-carbon homologs of naturally occurring side chains, excluding side chains which are negatively charged at physiological pH (e.g. carboxylate side chains). In some embodiments, the side chains are neutral. In other embodiments, the Z side chains are side chains of naturally occurring amino acids.
  • the optional Z subunits in some embodiments are selected from alanine, glycine, methionine, serine, and threonine.
  • the carrier peptide may include zero, one, two, or three Z subunits, and in some embodiments includes at most two Z subunits.
  • the carrier peptide has exactly two Y subunits of type Y a , which are contiguous or are flanking a cysteine subunit. In some embodiments, the two Y a subunits are contiguous.
  • side chains for Y a subunits include side chains of naturally occurring amino acids and one- or two- carbon homologs thereof, excluding side chains which are charged at physiological pH. Other possible side chains are side chains of naturally occurring amino acids.
  • the side chain is an aryl or aralkyl side chain; for example, each Y a may be independently selected from phenylalanine, tyrosine, tryptophan, leucine, isoleucine, and valine.
  • each Y a is independently selected from phenylalanine and tyrosine; in further embodiments, each Y a is phenylalanine.
  • One such conjugate includes a peptide having the formula
  • Arg9Phe 2 aa where aa is glycine or proline.
  • the foregoing carrier peptides may also comprise ILFQY, ILFQ, IWFQ or ILIQ.
  • Other embodiments include the foregoing carrier peptides which comprise the sequence PPMWS, PPMWT, PPMFS or PPMYS.
  • the peptide -oligomer conjugates of the invention are more effective than the unconjugated oligomer in various functions, including: inhibiting expression of targeted mRNA in a protein expression system, including cell free translation systems; inhibiting splicing of targeted pre-mRNA; and inhibiting replication of a virus, by targeting cis-acting elements which control nucleic acid replication or mRNA transcription of the virus.
  • conjugates of other pharmacological agents i.e., not a nucleic acid analog
  • some embodiments provide a conjugate comprising:
  • the carrier peptide comprises a glycine (G) or proline (P) amino acid subunit at a carboxy terminus of the carrier peptide and the carrier peptide is covalently attached to the pharmacological agent.
  • the carrier peptide in these embodiments may be any of the carrier peptides described herein. Methods for delivering the pharmacological agent by conjugating it to the carrier peptide are also provided.
  • the pharmacological agent to be delivered is may be a biologically active agent, e.g. a therapeutic or diagnostic agent, although it may be a compound employed for detection, such as a fluorescent compound.
  • Biologically active agents include drug substances selected from biomolecules, e.g. peptides, proteins, saccharides, or nucleic acids, particularly antisense oligonucleotides, or "small molecule” organic or inorganic compounds.
  • a "small molecule” compound may be defined broadly as an organic, inorganic, or organometallic compound which is not a biomolecule as described above. Typically, such compounds have molecular weights of less than 1000, or, in one embodiment, less than 500.
  • the pharmacological agent to be delivered does not include single amino acids, dipeptides, or tripeptides. In another embodiment, it does not include short oligopeptides; that is, oligopeptides having fewer than six amino acid subunits. In a further embodiment, it does not include longer oligopeptides; that is, oligopeptides having between seven and 20 amino acid subunits. In a still further embodiment, it does not include polypeptides, having greater than 20 amino acid subunits, or proteins.
  • the carrier peptide is effective to enhance the transport of the pharmacological agent into a cell relative to the pharmacological agent in unconjugated form and/or with less toxicity, relative to the pharmacological agent conjugated to a corresponding peptide lacking the glycing or proline subunits.
  • transport is enhanced by a factor of at least two, at least five or at least ten.
  • toxicity is decreased (i.e., maximum tolerated dose increased) by a factor of at least two, at least five or at least ten.
  • the carrier peptide can be linked to the agent to be delivered (e.g., nuceleic acid analogue, pharmacological agent, etc.) by a variety of methods available to one of skill in the art.
  • the carrier peptide is linked to the nucleic acid analogue directly without an intervening linker.
  • formation of an amide bond between the terminal amino acid and a free amine of free carboxyl on the nucleic acid analogue may be useful for forming the conjugate.
  • the carboxy terminal glycine or proline subunit is linked directly to the 3' end of the nucleic acid analogue, for example the carrier peptide may be linked by forming an amide bond between the carboxy terminal glycine or proline moiety and the 3' morpholino ring nitrogen (see e.g., Figure 1C).
  • the nucleic acid analog is conjugated to the carrier peptide via a linker moiety selected from a Y a or Y b subunit, a cysteine subunit, and an uncharged, non-amino acid linker moiety.
  • the nucleic acid analogue is linked to the carrier peptide directly via the glycine or proline moiety at either the 5 ' or 3' end of the nucleic acid analogue.
  • the carrier peptide is linked directly via the glycine or proline amino acid subunit to the 3 ' of the nucleic acid analogue, for example directly linked to the 3 ' morpholino nitrogen via an amide bond.
  • the conjugates comprise a linking moiety between the terminal glycine or proline amino acid subunit.
  • the linker is up to 18 atoms in length comprising bonds selected from alkyl, hydroxyl, alkoxy, alkylamino, amide, ester, carbonyl, carbamate, phosphorodiamidate, phosphoroamidate, phosphorothioate and phosphodiester.
  • the linker comprises phosphorodiamidate and piperazine bonds.
  • the linker has the following structure (XXIX):
  • R 24 is absent, H or Ci-C 6 alkyl.
  • R 24 is absent and in other embodiments structure (XXIX) links the 5 ' end of a nucleic acid analogue (e.g., a morpholino oligomer) to the carrier peptide (see e.g., Figure IB).
  • a nucleic acid analogue e.g., a morpholino oligomer
  • the linker between the carrier peptide and the nucleic acid analogue may also consist of natural or non-natural amino acids (e.g., 6-aminohexanoic acid or ⁇ -alanine).
  • the linker may also comprise a direct bond between the carboxy terminus of a transporter peptide and an amine or hydroxy group of the nucleic acid analogue (e.g., at the 3 ' morpholino nitrogen or 5 ' OH), formed by condensation promoted by e.g.
  • the linker may comprise any nonreactive moiety which does not interfere with transport or function of the conjugate.
  • Linkers can be selected from those which are non-cleavable under normal conditions of use, e.g., containing an ether, thioether, amide, or carbamate bond.
  • Bonds which are cleavable in vivo are known in the art and include, for example, carboxylic acid esters, which are hydrolyzed enzymatically, and disulfides, which are cleaved in the presence of glutathione. It may also be feasible to cleave a photolytically cleavable linkage, such as an ortho-nitrophenyl ether, in vivo by application of radiation of the appropriate wavelength.
  • exemplary heterobifunctional linking agents which further contain a cleavable disulfide group include N-hydroxysuccinimidyl 3-[(4- azidophenyl)dithio]propionate and others described in Vanin, E.F. and Ji, T.H., Biochemistry 20:6754-6760 (1981). *
  • the present disclosure provides a peptide oligomer conjugate, wherein the peptide comprises or consists of any one of the peptide sequences in Table 1.
  • the nucleic acid analogue comprises or consists of any of the oligonucleotide sequences in Table 1.
  • the present disclosure provides a peptide oligomer conjugate, wherein the peptide comprises or consists of any one of the peptide sequences in Table 1 , and the nucleic acid analogue comprises or consists of any of the oligonucleotide sequences in Table 1.
  • the disclosure provides a peptide comprising or consisting of any one of the sequences in Table 1.
  • eGFP654 GCTATTACCTTAACCCAG 17 huMSTN GAAAAAAGATTATATTGATTTTAAAATCATGCAA 18 target AAACTGCAACTCTGTGTT
  • CAG 12mer CAG CAG CAG CAG 40
  • CAG 15mer CAG CAG CAG CAG CAG CAG 41
  • CAG 18mer CAG CAG CAG CAG CAG CAG CAG CAG 42
  • CAG 25mer CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG CAG C 52
  • aa glycine or proline
  • B ⁇ -alanine
  • X 6-aminohexanoic acid
  • tg unmodifed amino terminus, or the amino terminal capped with an acetyl, benzoyl or stearoyl group (i.e, an acetyl amide, benzoyl amide or stearoyl amide)
  • Y b is: -C(0)-(CHR e ) n -NH- wherein n is 2 to 7 and each R e is independently, at each occurrence, hydrogen or methyl.
  • a terminal tg group not all sequences are noted with a terminal tg group; however, each of the above sequences may comprise an unmodifed amino terminus or an amino terminus capped with an acetyl, benzoyl or stearoyl group
  • Nucleic acid analogs included in the conjugates of the invention are substantially uncharged synthetic oligomers capable of base-specific binding to a target sequence of a polynucleotide, e.g. antisense oligonucleotide analogs.
  • Such analogs include, for example, methylphosphonates, peptide nucleic acids, substantially uncharged N3'- ⁇ P5' phosphoramidates, and morpholino oligomers.
  • the base sequence of the nucleic acid analog, provided by base pairing groups supported by the analog backbone can be any sequence, where the supported base pairing groups include standard or modified A, T, C, G and U bases or the non-standard inosine (I) and 7-deaza-G bases.
  • the nucleic acid analog is a morpholino oligomer, i.e. an oligonucleotide analog composed of morpholino subunit structures of the form shown in Fig. 1, where (i) the structures are linked together by phosphorus- containing linkages, one to three atoms long, preferably two atoms long, joining the morpholino nitrogen of one subunit to the 5' exocyclic carbon of an adjacent subunit, and (ii) Pi and Pj are purine or pyrimidine base-pairing moieties effective to bind, by base-specific hydrogen bonding, to a base in a polynucleotide.
  • a morpholino oligomer i.e. an oligonucleotide analog composed of morpholino subunit structures of the form shown in Fig. 1, where (i) the structures are linked together by phosphorus- containing linkages, one to three atoms long, preferably two atoms long, joining the morpholino nitrogen of one sub
  • the purine or pyrimidine base-pairing moiety is typically adenine, cytosine, guanine, uracil or thymine.
  • the synthesis, structures, and binding characteristics of morpholino oligomers are described further below and detailed in U.S. Patent Nos. 5,698,685,
  • Desirable chemical properties of the morpholino-based oligomers include the ability to selectively hybridize with a complementary-base target nucleic acid, including target RNA, with high Tm, even with oligomers as short as 8-14 bases, the ability to be actively transported into mammalian cells, and the ability of an oligomer:RNA heteroduplex to resist RNAse degradation.
  • the morpholino oligomer is about 8-40 subunits in length. More typically, the oligomer is about 8-20, about 8-16, about 10-30, or about 12-25 subunits in length.
  • antibacterial, short oligomers e.g. from about 8-12 subunits in length, can be especially advantageous, particularly when attached to a peptide transporter as disclosed herein.
  • One embodiment of the present disclosure is directed to peptide- oligomer conjugates comprising nucleic acid analogues (e.g., morpholino oligomers) comprising modified intersubunit linkages.
  • the conjugates have higher affinity for DNA and RNA than do the corresponding unmodified oligomers and demonstrate improved cell delivery, potency, and/or tissue distribution properties compared to oligomers having other intersubunit linkages.
  • the conjugates comprise one or more intersubunit linkages of type (A) as defined below.
  • the conjugates comprise at least one intersubunit linkage of type (B) as defined below.
  • the conjugates comprise intersubunit linkages of type (A) and type (B).
  • the conjugates comprise a morpholino oligomer as described in more detail below. The structural features and properties of the various linkage types and oligomers are described in more detail in the following discussion. 1.
  • the oligomers may optionally comprise one or more intersubunit linkages of type (A), and in certain embodiments the oligomers comprise at least one linkage of type (A), for example each linkage may be of type (A). In some other embodiments each linkage of type (A) has the same structure.
  • Linkages of type (A) may include linkages disclosed in co-owned U.S. Patent No. 7,943,762 which is hereby incorporated by reference in its entirety.
  • Linkage (A) has the following structure (I), wherein 3 ' and 5 ' indicate the point of attachment to the 3' and 5' ends, respectively, of the morpholino ring (i.e., structure (i) discussed below):
  • W is, at each occurrence, independently S or O;
  • X is, at each occurrence, independently -N(CH 3 ) 2 , -NR ⁇ R 2 , -OR 3 or ;
  • Y is, at each occurrence, independently O or -NR 2 ,
  • R 1 is, at each occurrence, independently hydrogen or methyl
  • R 2 is, at each occurrence, independently hydrogen or -LNR 4 R 5 R 7 ;
  • R 3 is, at each occurrence, independently hydrogen or Ci-C 6 alkyl
  • R 5 is, at each occurrence, independently hydrogen, methyl or an electron pair
  • R 6 is, at each occurrence, independently hydrogen or methyl
  • R 7 is, at each occurrence, independently hydrogen Ci-C 6 alkyl or Ci-C 6 alkoxyalkyl
  • L is an optional linker up to 18 atoms in length comprising alkyl, alkoxy or alkylamino groups, or combinations thereof.
  • the oligomer comprises at least one linkage of type (A).
  • the oligomer includes at least two consecutive linkages of type (A).
  • at least 5% of the linkages in the oligomer are type (A); for example in some embodiments, 5%-95%, 10% to 90%, 10%> to 50%), or 10%o to 35% of the linkages may be linkage type (A).
  • at least one type (A) linkage is -N(CH 3 ) 2 .
  • each linkage of type (A) is -N(CH 3 ) 2 , and in even other embodiments each linkage in the oligomer is -N(CH 3 ) 2 .
  • at least one type (A) linkage is piperizin- 1-yl, for example unsubstituted piperazin-l-yl (e.g., A2 or A3).
  • each linkage of type (A) is piperizin-l-yl, for example unsubstituted piperazin-l-yl.
  • W is, at each occurrence, independently S or O, and in certain embodiments W is O.
  • X is, at each occurrence, independently
  • X is -N(CH 3 ) 2 .
  • X is -NR J R 2 , and in other examples X is -OR 3 .
  • R 1 is, at each occurrence, independently hydrogen or methyl. In some embodiments, R 1 is hydrogen. In other embodiments X is methyl.
  • R 2 is, at each occurrence, hydrogen. In other embodiments R 2 is, at each occurrence, -LNR 4 R 5 R 7 .
  • R 3 is, at each occurrence, independently hydrogen or Ci-C 6 alkyl. In other embodiments, R 3 is methyl. In yet other embodiments, R 3 is ethyl. In some other embodiments, R 3 is n- propyl or isopropyl. In some other embodiments, R 3 is C 4 alkyl. In other embodiments, R 3 is C 5 alkyl. In some embodiments, R 3 is C 6 alkyl.
  • R 5 is, at each occurrence, independently hydrogen, methyl or an electron pair. In some embodiments, R 5 is hydrogen. In other embodiments, R 5 is methyl. In yet other embodiments, R 5 is an electron pair.
  • R 6 is, at each occurrence, independently hydrogen or methyl. In some embodiments, R 6 is hydrogen. In other embodiments, R 6 is methyl.
  • R 7 is, at each occurrence, independently hydrogen Ci-C 6 alkyl or C 2 -C 6 alkoxyalkyl. In some embodiments R7 is hydrogen. In other embodiments, R 7 is Ci-C 6 alkyl. In yet other embodiments, R 7 is C 2 -C 6 alkoxyalkyl. In some embodiments, R 7 is methyl. In other embodiments, R 7 is ethyl. In yet other embodiments, R 7 is n-propyl or isopropyl. In some other embodiments, R 7 is C 4 alkyl. In some embodiments, R 7 is C 5 alkyl. In some embodiments, R 7 is C 6 alkyl. In yet other embodiments, R 7 is C 2 alkoxyalkyl.
  • R 7 is C 3 alkoxyalkyl. In yet other embodiments, R 7 is C 4 alkoxyalkyl. In some embodiments, R 7 is C 5 alkoxyalkyl. In other embodiments, R 7 is C 6 alkoxyalkyl.
  • the linker group L contains bonds in its backbone selected from alkyl (e.g. -CH 2 -CH 2 -), alkoxy (e.g., -C-0-C-), and alkylamino (e.g. - CH 2 -NH-), with the proviso that the terminal atoms in L (e.g., those adjacent to carbonyl or nitrogen) are carbon atoms.
  • alkyl e.g. -CH 2 -CH 2 -
  • alkoxy e.g., -C-0-C-
  • alkylamino e.g. - CH 2 -NH-
  • the linker is generally unbranched.
  • the linker is a hydrocarbon linker.
  • Such a linker may have the structure (01 ⁇ 4) ⁇ -, where n is 1-12, preferably 2-8, and more preferably 2-6.
  • Oligomers having any number of linkage type (A) are provided.
  • the oligomer contains no linkages of type (A).
  • 5, 10, 20, 30, 40, 50, 60, 70, 80 or 90 percent of the linkages are linkage (A).
  • 10 to 80, 20 to 80, 20 to 60, 20 to 50, 20 to 40, or 20 to 35 percent of the linkages are linkage (A).
  • each linkage is type (A).
  • the oligomers comprise at least one linkage of type (B).
  • the oligomers may comprise 1, 2, 3, 4, 5, 6 or more linkages of type (B).
  • the type (B) linkages may be adjacent or may be interspersed throughout the oligomer.
  • Linkage type (B) has the following structure (I):
  • W is, at each occurrence, independently S or O;
  • X is, at each occurrence, independently -NR 8 R 9 or -OR 3 ;
  • Y is, at each occurrence, independently O or -NR 10 ,
  • R 3 is, at each occurrence, independently hydrogen or Ci-C 6 alkyl
  • R 8 is, at each occurrence, independently hydrogen or C2-C12 alkyl
  • R 9 is, at each occurrence, independently hydrogen, C1-C12 alkyl, C1-C12 aralkyl or aryl
  • R 10 is, at each occurrence, independently hydrogen, C1-C12 alkyl or
  • R 8 and R 9 may join to form a 5-18 membered mono or bicyclic heterocycle or R 8 , R 9 or R 3 may join with R 10 to form a 5-7 membered heterocycle, and wherein when X is 4-piperazino, X has the following structure (III):
  • R 11 is, at each occurrence, independently C 2 -Ci 2 alkyl, Ci-Ci 2 aminoalkyl, Ci-Ci 2 alkylcarbonyl, aryl, heteroaryl or heterocyclyl;
  • R is, at each occurrence, independently an electron pair, hydrogen or Ci-
  • R 12 is, at each occurrence, independently, hydrogen, Ci-Ci 2 alkyl, Ci-Ci 2 aminoalkyl, -NH 2 , -CONH 2 , -NR 13 R 14 , -NR 13 R 14 R 15 , C1-C12 alkylcarbonyl, oxo, -CN, trifluoromethyl, amidyl, amidinyl, amidinylalkyl, amidinylalkylcarbonyl guanidinyl, guanidinylalkyl, guanidinylalkylcarbonyl, cholate, deoxycholate, aryl, heteroaryl, heterocycle, -SR 13 or Ci-Ci 2 alkoxy, wherein R 13 , R 14 and R 15 are, at each occurrence, independently Ci-Ci 2 alkyl.
  • the oligomer comprises one linkage of type (B). In some other embodiments, the oligomer comprises two inkages of type (B). In some other embodiments, the oligomer comprises three linkages of type (B). In some other embodiments, the oligomer comprises four linkages of type (B). In still other embodiments, the linkages of type (B) are consecutive (i.e., the type (B) linkages are adjacent to each other). In further embodiments, at least 5% of the linkages in the oligomer are type (B); for example in some embodiments, 5%-95%, 10% to 90%>, 10%> to 50%), or 10%) to 35%o of the linkages may be linkage type (B).
  • R 3 is, at each occurrence, independently hydrogen or Ci-C 6 alkyl. In yet other embodiments, R 3 may be methyl. In some embodiments, R 3 may be ethyl. In some other embodiments, R may be n-propyl or isopropyl. In yet other embodiments, R 3 may be C 4 alkyl. In some embodiments, R 3 may be C 5 alkyl. In some embodiments, R 3 may be C 6 alkyl.
  • R 8 is, at each occurrence, independently hydrogen or C 2 -Ci 2 alkyl. In some embodiments, R 8 is hydrogen. In yet other embodiments, R 8 is ethyl. In some other embodiments, R 8 is n-propyl or isopropyl. In some embodiments, R 8 is C 4 alkyl. In yet other embodiments, R 8 is C 5 alkyl. In other embodiments, R 8 is C 6 alkyl. In some embodiments, R 8 is C 7 alkyl. In yet other embodiments, R 8 is Cs alkyl. In other embodiments, R 8 is C9 alkyl. In yet other embodiments, R 8 is Cio alkyl. In some other embodiments, R 8 is Cn alkyl.
  • R 8 is Ci 2 alkyl. In some other embodiments, R 8 is C 2 -Ci 2 alkyl and the C2-C12 alkyl includes one or more double bonds (e.g., alkene), triple bonds (e.g., alkyne) or both. In some embodiments, R 8 is unsubstituted C2-C12 alkyl.
  • R 9 is, at each occurrence, independently hydrogen, C1-C12 alkyl, C1-C12 aralkyl or aryl. In some embodiments, R 9 is hydrogen. In yet other embodiments, R 9 is C1-C12 alkyl. In other embodiments, R 9 is methyl. In yet other embodiments, R 9 is ethyl. In some other embodiments, R 9 is n-propyl or isopropyl. In some embodiments, R 9 is C 4 alkyl. In some embodiments, R 9 is C 5 alkyl. In yet other embodiments, R 9 is C 6 alkyl. In some other embodiments, R 9 is C 7 alkyl. In some embodiments, R 9 is Cs alkyl. In some embodiments, R 9 is C9 alkyl. In some other embodiments, R 9 is C10 alkyl. In some other embodiments, R 9 is Cn alkyl. In yet other embodiments, R 9 is C12 alkyl.
  • R 9 is C1-C12 aralkyl.
  • R 9 is benzyl and the benzyl may be optionally substituted on either the phenyl ring or the benzylic carbon.
  • Substituents in this regards include alkyl and alkoxy groups, for example methyl or methoxy.
  • the benzyl group is substituted with methyl at the benzylic carbon.
  • R 9 has the following structure (XIV):
  • R 9 is aryl.
  • R 9 is phenyl, and the phenyl may be optionally substituted. Substituents in this regard substitutuents include alkyl and alkoxy groups, for example methyl or methoxy.
  • R 9 is phenyl and the phenyl comprises a crown ether moiety, for example a 12-18 membered crown ether. In one embodiment the crown ether is 18 membered and may further comprise and additional phenyl moiety.
  • R 9 has one of the following structures (XV) or XVI):
  • R is, at each occurrence, independently hydrogen, C -Cn alkyl or -LNR 4 R 5 R 7 , wherein R 4 , R 5 and R 7 are as defined above with respect to linkage (A).
  • R 10 is hydrogen.
  • R 10 is C 1 -C 12 alkyl, and in other embodimens R 10 is -LNR 4 R 5 R 7 .
  • R 10 is methyl.
  • R 10 is ethyl.
  • R 10 is C3 alkyl.
  • R 10 is C 4 alkyl.
  • R 10 is C 5 alkyl.
  • R 10 is C 6 alkyl.
  • R 10 is C 7 alkyl. In yet other embodiments, R 10 is Cs alkyl. In some embodiments, R 10 is C9 alkyl. In other embodiments, R 10 is C 10 alkyl. In yet other embodiments, R 10 is Cn alkyl. In some other embodiments, R 10 is C 12 alkyl.
  • R 8 and R 9 join to form a 5-18 membered mono or bicyclic heterocycle.
  • the heterocycle is a 5 or 6 membered monocyclic heterocycle.
  • linkage (B) has the following structure (IV):
  • Z represents a 5 or 6 membered monocyclic heterocycle.
  • heterocycle is bicyclic, for example a 12- membered bicyclic heterocycle.
  • the heterocycle may be piperizinyl.
  • the heterocycle may be morpholino.
  • the heterocycle may be piperidinyl.
  • the heterocycle may be decahydroisoquinoline.
  • Representative heterocycles include the following:
  • R 11 is, at each occurrence, independently C2-C12 alkyl, C1-C12 aminoalkyl, aryl, heteroaryl or heterocyclyl.
  • R 11 is C2-C12 alkyl. In some embodiments, R 11 is ethyl. In other embodiments, R 11 is C3 alkyl. In yet other embodiments, R 11 is isopropyl. In some other embodiments, R 11 is C 4 alkyl. In other embodiments, R 11 is C 5 alkyl. In some embodiments, R 11 is C 6 alkyl. In other embodiments, R 11 is C 7 alkyl. In some embodiments, R 11 is Cs alkyl. In other embodiments, R 11 is C9 alkyl. In yet other embodiments, R 11 is C 10 alkyl. In some other embodiments, R 11 is Cn alkyl. In some embodiments, R 11 is C 12 alkyl.
  • R 11 is C1-C12 aminoalkyl. In some embodiments, R 11 is methylamino. In some embodiments, R 11 is ethylamino. In other embodiments, R 11 is C3 aminoalkyl. In yet other embodiments, R 11 is C 4 aminoalkyl. In some other embodiments, R 11 is C 5 aminoalkyl. In other embodiments, R 11 is C 6 aminoalkyl. In yet other embodiments, R 11 is C 7 aminoalkyl. In some embodiments, R 11 is Cg aminoalkyl. In other embodiments, R 11 is C9 aminoalkyl. In yet other embodiments, R 11 is Cio aminoalkyl. In some other embodiments, R 11 is Cn aminoalkyl.
  • R 11 is C 12 aminoalkyl. In other embodiments, R 11 is C 1 -C 12 alkylcarbonyl. In yet other embodiments, R 11 is Ci alkylcarbonyl. In other embodiments, R 11 is C 2 alkylcarbonyl. In some embodiments, R 11 is C 3 alkylcarbonyl. In yet other embodiments, R 11 is C 4 alkylcarbonyl. In some embodiments, R 11 is C 5 alkylcarbonyl. In some other embodiments, R 11 is C 6 alkylcarbonyl. In other embodiments, R 11 is C 7 alkylcarbonyl. In yet other embodiments, R 11 is Cg alkylcarbonyl. In some embodiments, R 11 is C 9 alkylcarbonyl. In yet other embodiments, R 11 is C 10 alkylcarbonyl. In some other embodiments, R 11 is Cn alkylcarbonyl. In some embodiments, R 11 is C 12
  • n is 1.
  • n is 2.
  • n is 3.
  • n is 4.
  • n is 5.
  • n is 6.
  • R 11 is aryl.
  • R 11 is phenyl.
  • the phenyl is substituted, for example with a nitro group.
  • R 11 is heteroaryl.
  • R 11 is pyridinyl.
  • R 11 is pyrimidinyl.
  • R 11 is heterocyclyl.
  • R 11 is piperidinyl, for example piperidin-4-yl.
  • R is an electron pair. In other embodiments, R is hydrogen, and in other embodiments R is C 1 -C 12 alkyl. In some embodiments, R is methyl. In some embodiments, R is ethyl. In other embodiments, R is C 3 alkyl. In yet other embodiments, R is isopropyl. In some other embodiments, R is C 4 alkyl. In yet other embodiments, R is C 5 alkyl. In some embodiments, R is C 6 alkyl. In other embodiments, Ris C 7 alkyl. In yet other embodiments, R is Cg alkyl. In other embodiments, R is C 9 alkyl. In some embodiments, R is C 10 alkyl. In yet other embodiments, R is Cn alkyl. In some embodiments, R is C 12 alkyl.
  • R 12 is, at each occurrence, independently, hydrogen, C1-C12 alkyl, C1-C12 aminoalkyl, -NH 2 , -CONH 2 ,-NR 13 R 14 , -NR 13 R 14 R 15 , oxo, -CN, trifluoromethyl, amidyl, amidinyl, amidinylalkyl, amidinylalkylcarbonyl guanidinyl, guanidinylalkyl, guanidinylalkylcarbonyl, cholate, deoxycholate, aryl, heteroaryl, heterocycle, -SR 13 or C 1 -C 12 alkoxy, wherein R 13 , R 14 and R 15 are, at each occurrence, independently C 1 -C 12 alkyl
  • R 12 is hydrogen. In some embodiments, R 12 is C 1 -C 12 alkyl. In some embodiments, R 12 is C 1 -C 12 aminoalkyl. In some embodiments, R 12 is -NH 2 . In some embodiments, R 12 is -CONH 2 . In some embodiments, R 12 is -NR 13 R 14 . In some embodiments, R 12 is -NR 13 R 14 R 15 . In some embodiments, R 12 is Ci- C 12 alkylcarbonyl. In some embodiments, R 12 is oxo. In some embodiments, R 12 is - CN. In some embodiments, R 12 is trifluoromethyl. In some embodiments, R 12 is amidyl.
  • R 12 is amidinyl. In some embodiments, R 12 is amidinylalkyl. In some embodiments, R 12 is amidinylalkylcarbonyl. In some embodiments, R 12 is guanidinyl, for example mono methylguanidynyl or
  • R 12 is guanidinylalkyl. In some embodiments, R 12 is amidinylalkylcarbonyl. In some embodiments, R 12 is cholate. In some embodiments, R 12 is deoxycholate. In some embodiments, R 12 is aryl. In some embodiments, R 12 is heteroaryl. In some embodiments, R 12 is heterocycle. In some embodiments, R 12 is -SR 13 . In some embodiments, R 12 is C 1 -C 12 alkoxy. In some embodiments, R 12 is dimethyl amine.
  • R 12 is methyl. In yet other embodiments, R 12 is ethyl. In some embodiments, R 12 is C 3 alkyl. In some embodiments, R 12 is isopropyl. In some embodiments, R 12 is C 4 alkyl. In other embodiments, R 12 is C 5 alkyl. In yet other embodiments, R 12 is C 6 alkyl. In some other embodiments, R 12 is C 7 alkyl. In some embodiments, R 12 is Cs alkyl. In yet other embodiments, R 12 is C 9 alkyl. In some embodiments, R 12 is C 10 alkyl. In yet other embodiments, R 12 is Cn alkyl. In other embodiments, R 12 is C 12 alkyl. In yet other embodiments, the alkyl moiety is substituted with one or more oxygen atom to form an ether moiety, for example a methoxymethyl moiety.
  • R 12 is methylamino. In other embodiments, R 12 is ethylamino. In yet other embodiments, R 12 is C 3 aminoalkyl. In some embodiments, R 12 is C 4 aminoalkyl. In yet other embodiments, R 12 is C5 aminoalkyl. In some other embodiments, R 12 is C 6 aminoalkyl. In some embodiments, R 12 is C 7 aminoalkyl. In some embodiments, R 12 is Cg aminoalkyl. In yet other embodiments, R 12 is C 9 aminoalkyl. In some other embodiments, R is C 10 aminoalkyl. In yet other embodiments, R 12 is Cn aminoalkyl. In other embodiments, R 12 is C 12 aminoalkyl. In some embodiments, the amino alkyl is a dimethylamino alkyl.
  • R 12 is acetyl. In some other embodiments, R 12 is C 2 alkylcarbonyl. In some embodiments, R 12 is C 3 alkylcarbonyl. In yet other embodiments, R 12 is C 4 alkylcarbonyl. In some embodiments, R 12 is C5 alkylcarbonyl. In yet other embodiments, R 12 is C 6 alkylcarbonyl. In some other embodiments, R 12 is C 7 alkylcarbonyl. In some embodiments, R 12 is Cg alkylcarbonyl. In yet other embodiments, R 12 is C 9 alkylcarbonyl. In some other embodiments, R 12 is C 10 alkylcarbonyl. In some embodiments, R 12 is Cn alkylcarbonyl.
  • R 12 is C 12 alkylcarbonyl.
  • the alkylcarbonyl is substituted with a carboxy moiety, for example the alkylcarbonyl is substituted to form a succinic acid moiety (i.e., a 3- carboxy alkylcarbonyl).
  • the alkylcarbonyl is substituted with a terminal -SH group.
  • R 12 is amidyl.
  • the amidyl comprises an alkyl moiety which is further substituted, for example with -SH, carbamate, or combinations thereof.
  • the amidyl is substituted with an aryl moiety, for example phenyl.
  • R 12 may have the following structure (IX):
  • R 16 is, at each occurrence, independently hydrogen, alkyl, Ci-Ci 2 alkoxy, -CN, aryl or heteroaryl.
  • R 12 is methoxy. In other embodiments, R 12 is ethoxy. In yet other embodiments, R 12 is C 3 alkoxy. In some embodiments, R 12 is C 4 alkoxy. In some embodiments, R 12 is C 5 alkoxy. In some other embodiments, R 12 is C 6 alkoxy. In other embodiments, R 12 is C 7 alkoxy. In some other embodiments, R 12 is Cs alkoxy. In some embodiments, R 12 is C 9 alkoxy. In other embodiments, R 12 is C 10 alkoxy. In some embodiments, R is Cn alkoxy. In yet other embodiments, R is C 12 alkoxy.
  • R 12 is pyrrolidinyl, for example pyrrolidin-l-yl.
  • R 12 is piperidinyl, for example piperidin-l-yl or piperidin-4-yl.
  • R 12 is morpholino, for example morpholin-4-yl.
  • R 12 is phenyl, and in even further embodiments, the phenyl is substituted, for example with a nitro group.
  • R 12 is pyrimidinyl, for example pyrimidin-2-yl.
  • R 13 , R 14 and R 15 are, at each occurrence, independently C1-C12 alkyl. In some embodiments, R 13 , R 14 or R 15 is methyl. In yet other embodiments, R 13 , R 14 or R 15 is ethyl. In other embodiments, R 13 , R 14 or R 15 is C3 alkyl. In yet other embodiments, R 13 , R 14 or R 15 is isopropyl. In other embodiments, R 13 , R 14 or R 15 is C 4 alkyl. In some embodiments, R 13 , R 14 or R 15 is C 5 alkyl. In some other embodiments, R 13 , R 14 or R 15 is C 6 alkyl.
  • R 13 , R 14 or R 15 is C 7 alkyl. In yet other embodiments, R 13 , R 14 or R 15 is Cs alkyl. In other embodiments, R 13 , R 14 or R 15 is C 9 alkyl. In some embodiments, R 13 , R 14 or R 15 is C 10 alkyl. In some embodiments, R 13 , R 14 or R 15 is Cn alkyl. In yet other embodiments, R 13 , R 14 or R 15 is C12 alkyl.
  • R 12 is amidyl substituted with an aryl moiety.
  • each occurrence of R 16 may be the same or differerent.
  • R 16 is hydrogen.
  • R 16 is -CN.
  • R 16 is heteroaryl, for example tretrazolyl.
  • R 16 is methoxy.
  • R 16 is aryl, and the aryl is optionally substituted.
  • Optional substitutents in this regard include: C1-C12 alkyl, Ci- C12 alkoxy, for example methoxy; trifluoromethoxy; halo, for example chloro; and trifluoromethyl.
  • R 16 is methyl. In yet other embodiments, R 16 is ethyl. In some embodiments, R 16 is C3 alkyl. In some other embodiments, R 16 is isopropyl. In yet other embodiments, R 16 is C 4 alkyl. In other embodiments, R 16 is C 5 alkyl. In yet other embodiments, R 16 is C 6 alkyl. In some other embodiments, R 16 is C 7 alkyl. In some embodiments, R 16 is Cs alkyl. In yet other embodiments, R 16 is C9 alkyl. In some other embodiments, R is C 10 alkyl. In other embodiments, R is Cn alkyl. In some other embodiments, R 16 is C 12 alkyl.
  • R 16 is methoxy. In some embodiments, R 16 is ethoxy. In yet other embodiments, R 16 is C 3 alkoxy. In some other embodiments, R 16 is C 4 alkoxy. In other embodiments, R 16 is C 5 alkoxy. In some other embodiments, R 16 is C 6 alkoxy. In yet other embodiments, R 16 is C 7 alkoxy. In some other embodiments, R 16 is C8 alkoxy. In yet other embodiments, R 16 is C9 alkoxy. In some other embodiments, R 16 is C 10 alkoxy. In some embodiments, R 16 is Cn alkoxy. In some other embodiments, R 16 is C 12 alkoxy.
  • R 8 and R 9 join to form a 12-18 membered crown ether.
  • the crown ether s 18 membered, and in other embodiments the crown ether is 15 membered.
  • R 8 and R 9 join to form a heterocycle having one of the following structures (X) or (XI):
  • R 8 , R 9 or R 3 join with R 10 to form a 5-7 membered heterocycle.
  • R 3 joins with R 10 to form a 5-7 membered heterocycle.
  • the heterocycle is 5-membered.
  • the heterocycle is 6-membered.
  • the heterocycle is 7-memebered.
  • the heterocycle is represented by the following structure (XII):
  • linkage (B) may have one of the following structures (Bl), (B2) or (B3):
  • R 12 is C 1 -C 12 alkylcarbonyl or amidyl which is further substituted with an arylphosphoryl moiety, for example a triphenyl phosporyl moiety.
  • linkages having this structure include B56 and B55
  • linkage (B) does not have any of the structures A1-A5.
  • Table 2 shows representative linkages of type (A) and (B).
  • a base comprising a PMO apn linkage is illustrated as apn B, where B is a base.
  • Other linkages are designated similarily.
  • abbreviated designations may be used, for example, the abbreviated designations in parenthses above may be used (e.g., a B, refers to apn B). Other readily identifiable abbreviations may also be used.
  • the conjugate may also comprise an oligomer comprising modified terminal groups. Applicants have found that
  • the modified terminal groups comprise a hydrophobic moiety, while in other embodiments the modified terminal groups comprise a hydrophilic moiety.
  • the modified terminal groups may be present with or without the linkages described above.
  • the oligomers to which the carrier peptide is conjugated comprise one or more modified terminal groups and linkages of type (A), for example linkages wherein X is -N(CH 3 ) 2 .
  • the oligomers comprise one or more modified terminal group and linkages of type (B), for example linkages wherein X is 4- aminopiperidin-l-yl (i.e., APN).
  • the oligomers comprise one or more modified terminal group and a mixture of linkages (A) and (B).
  • the oligomers may comprise one or more modified terminal group (e.g., trityl or triphenyl acetyl) and linkages wherein X is -N(CH 3 ) 2 and linkages wherein X is 4- aminopiperidin-l-yl.
  • modified terminal groups and modified linkages also provide favorable therapeutic properties to the oligomers.
  • the oligomers comprising terminal modifications have the following structure (XVII): 5' terminus
  • R 17 is, at each occurrence, independently absent, hydrogen or Ci-C 6 alkyl
  • Pi is independently, at each occurrence, a base-pairing moiety
  • L 1 is an optional linker up to 18 atoms in length comprising bonds selected from alkyl, hydroxyl, alkoxy, alkylamino, amide, ester, disulfide, carbonyl, carbamate, phosphorodiamidate, phosphoroamidate, phosphorothioate, piperazine and phosphodiester; and
  • x is an integer of 0 or greater; and wherein at least one of R 18 or R 19 is
  • R 18 or R 1 i 9 y is R 2"0 u and provided that both of R and R 18 are not absent.
  • the oligomers with modified terminal groups may comprise any number of linkages of types (A) and (B).
  • the oligomers may comprise only linkage type (A).
  • X in each linkage may be -N(CH 3 ) 2 .
  • the oligomers may only comprise linkage (B).
  • the oligomers comprise a mixture of linkages (A) and (B), for example from 1 to 4 linkages of type (B) and the remainder of the linkages being of type (A).
  • Linkages in this regard include, but are not limited to, linkages wherein X is aminopiperidinyl for type (B) and dimethyl amino for type (A).
  • R 17 is absent. In some embodiments, R 17 is hydrogen. In some embodiments, R 17 is Ci-C 6 alkyl. In some embodiments, R 17 is methyl. In yet other embodiments, R 17 is ethyl. In some embodiments, R 17 is C 3 alkyl. In some other embodiments, R 17 is isopropyl. In other embodiments, R 17 is C 4 alkyl. In yet other embodiments, R 17 is C 5 alkyl. In some other embodiments, R 17 is C 6 alkyl.
  • R 18 is absent. In some embodiments, R 18 is hydrogen. In some embodiments, R 18 is the carrier peptide. In some embodiments, R 18 is a natural or non-natural amino acid, for example trimethylglycine. In some embodiments, R 18 is R 20 .
  • R 20 is, at each occurrence, independently guanidinyl, heterocyclyl, C1-C30 alkyl, C3-C8 cycloalkyl; C6-C30 aryl, C7-C30 aralkyl, C C 30 alkylcarbonyl, C 3 -C 8 cycloalkylcarbonyl, C 3 -C 8 cycloalkylalkylcarbonyl, C 6 -C 30 arylcarbonyl, C7-C30 aralkylcarbonyl, C 2 -C30 alkyloxycarbonyl, C3-C8
  • R is C 1 -C30 alkyl comprising one or more oxygen or hydroxyl moieties or combinations thereof and each R 22 is C 6 -C 12 aryloxy.
  • R 20 is, at each occurrence, independently guanidinyl, heterocyclyl, Ci-C 30 alkyl, C 3 -C 8 cycloalkyl; C 6 -C 30 aryl, C3-C30 alkylcarbonyl, C3-C8 cycloalkylcarbonyl, C3-C8 cycloalkylalkylcarbonyl, C7-C30 arylcarbonyl, C7-C30 aralkylcarbonyl, C 2 -C 30 alkyloxycarbonyl, C 3 -C 8
  • R 20 is guanidinyl, for example mono methylguanidynyl or dimethylguanidinyl.
  • R 20 is heterocyclyl.
  • R 20 is piperidin-4-yl.
  • the piperidin-4-yl is substituted with trityl or Boc groups.
  • R 20 is C 3 Cs cycloalkyl.
  • R 20 is C6-C30 aryl.
  • R is C 7 -C30 arylcarbonyl.
  • R 20 has the following structure (XVIII):
  • R ZJ is, at each occurrence, independently hydrogen, halo, C 1 -C30 alkyl, C 1 -C30 alkoxy, Ci-C 30 alkyloxycarbonyl, C 7 -C30 aralkyl, aryl, heteroaryl, heterocyclyl or heterocyclalkyl, and wherein one R 23 may join with another R 23 to form a heterocyclyl ring.
  • at least one R 23 is hydrogen, for example, in some embodiments, each R 23 is hydrogen.
  • at least one R 23 is Ci-C 30 alkoxy, for example in some embodiments, each R 23 is methoxy.
  • At least one R 23 is heteroaryl, for example in some embodiments, at least one R 23 has one of the following structures (XVIII a) of (XVIIIb):
  • one R joins with another R to form a heterocyclyl ring.
  • R is 5-carboxyfluorescein.
  • R is C 7 -C 3 o aralkylcarbonyl.
  • R has one of the following structures (XIX), (XX) or (XXI):
  • R 23 is, at each occurrence, independently hydrogen, halo, C1-C30 alkyl, C1-C30 alkoxy, Ci-C 30 alkyloxycarbonyl, C7-C30 aralkyl, aryl, heteroaryl, heterocyclyl or heterocyclalkyl, wherein one R 23 may join with another R 23 to form a heterocyclyl ring, X is -OH or halo and m is an integer from 0 to 6. In some specific embodiments, m is 0. In other embodimens, m is 1, while in other embodiments, m is 2. In other embodiments, at least one R 23 is hydrogen, for example in some embodiments each R 23 is hydrogen. In some embodiments, X is hydrogen. In other embodiments, X is -OH. In other embodiments, X is CI. In other embodiments, at least one R 23 is Ci-C 3 o alkoxy, for example methoxy.
  • R 20 is C 7 -C 3 o aralkyl, for example trityl. In other embodiments, R 20 is methoxy trityl. In some embodiments, R 20 has the following structure (XXII):
  • R 23 is, at each occurrence, independently hydrogen, halo, C1-C30 alkyl, C1-C30 alkoxy, Ci-C 30 alkyloxycarbonyl, C7-C30 aralkyl, aryl, heteroaryl, heterocyclyl or heterocyclalkyl, and wherein one R 23 may join with another R 23 to form a heterocyclyl ring.
  • each R 23 is hydrogen.
  • at least one R 23 is Ci-C 3 o alkoxy, for example methoxy.
  • R 20 is C 7 -C 3 o aralkyl and R 20 has the following structure (XXIII):
  • At least one R 23 is halo, for example chloro. In some other embodiments, one R 23 is chloro in the para position.
  • R 20 is Ci-C 3 o alkyl.
  • R 20 is a C4-C20 alkyl and optionally comprises one or more double bonds.
  • R 20 is a C4-10 alkyl comprising a triple bond, for example a terminal triple bond.
  • R 20 is hexyn-6-yl.
  • R 20 has one of the following structures (XXIV), (XXV), (XXVI) or (XXVII):
  • R 20 is a C3-C30 alkylcarbonyl, for
  • p is an integer from 1 to 6 and Het is a heteroaryl.
  • Het is a heteroaryl.
  • Het is pyridinyl, for example pyridin-2-yl.
  • the C3-C30 alkylcarbonyl is substituted with a further oligomer, for example in some embodiments the oligomer comprises a C3-C30 alkyl carbonyl at the 3 ' position which links the oligomer to the 3 ' position of another oligomer.
  • Such terminal modifications are included within the scope of the present disclosure.
  • R is a C3-C30 alkyl carbonyl which is futher substituted with an arylphosphoryl moiety, for example triphenyl phosphoryl.
  • R 20 groups examples include structure 33 in Table 3.
  • R is C3-C8 cycloalkylcarbonyl, for example C5-C7 alkyl carbonyl.
  • R 2 o has the following structure (XXVIII):

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des analogues d'oligonucléotide conjugués à des peptides porteurs. Les composés selon la présente invention sont utiles dans le traitement de diverses maladies, par exemple de maladies pour lesquelles l'inhibition de l'expression protéique ou la correction de produits d'épissage ARNm aberrants produit des effets thérapeutiques bénéfiques.
EP11793913.2A 2011-05-05 2011-11-17 Conjugués peptides/oligonucléotides Pending EP2704749A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/101,942 US20110269665A1 (en) 2009-06-26 2011-05-05 Compound and method for treating myotonic dystrophy
US13/107,528 US9238042B2 (en) 2010-05-13 2011-05-13 Antisense modulation of interleukins 17 and 23 signaling
PCT/US2011/061282 WO2012150960A1 (fr) 2011-05-05 2011-11-17 Conjugués peptides/oligonucléotides

Publications (1)

Publication Number Publication Date
EP2704749A1 true EP2704749A1 (fr) 2014-03-12

Family

ID=45218873

Family Applications (1)

Application Number Title Priority Date Filing Date
EP11793913.2A Pending EP2704749A1 (fr) 2011-05-05 2011-11-17 Conjugués peptides/oligonucléotides

Country Status (8)

Country Link
EP (1) EP2704749A1 (fr)
JP (6) JP6478632B2 (fr)
KR (3) KR102183273B1 (fr)
CN (2) CN107693797B (fr)
AU (5) AU2011367230B2 (fr)
CA (2) CA2834128A1 (fr)
IL (2) IL273838B (fr)
WO (1) WO2012150960A1 (fr)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
EP2049664B1 (fr) 2006-08-11 2011-09-14 Prosensa Technologies B.V. Oligonucléotides monocaténaires complémentaires des elements repetitifs pour le traitement de troubles génétiques associés a l'instabilité des répétitions de l'ADN
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
DK2203173T3 (en) 2007-10-26 2016-02-29 Academisch Ziekenhuis Leiden Materials and methods for prevention of muscle diseases
EP2119783A1 (fr) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Procédé pour l'omission efficace de l'exon (44) dans la dystrophie musculaire de Duchenne et moyens connexes
CN102203253B (zh) 2008-10-24 2016-04-06 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
KR102113306B1 (ko) 2009-11-12 2020-05-21 더 유니버시티 오브 웨스턴 오스트레일리아 안티센스 분자 및 이를 이용한 질환 치료방법
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR20140097398A (ko) * 2011-11-18 2014-08-06 사렙타 쎄러퓨틱스, 인코퍼레이티드 기능적으로-변형된 올리고뉴클레오티드 및 이의 서브유니트
US9944926B2 (en) 2011-11-30 2018-04-17 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
EP2785729B1 (fr) 2011-11-30 2020-11-04 Sarepta Therapeutics, Inc. Oligonucléotides pour le traitement de maladies à répétition étendue
US9326992B2 (en) 2011-12-08 2016-05-03 Sarepta Therapeutics, Inc. Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
CN104203289B (zh) 2012-01-27 2020-11-03 比奥马林技术公司 用于治疗杜兴型肌营养不良症和贝克型肌营养不良症的具有改善特性的rna调节性寡核苷酸
RS56319B1 (sr) 2012-04-23 2017-12-29 Biomarin Tech Bv Oligonukleotidi koji moduliraju rnk sa poboljšanim karakteristikama za lečenje neuromišićnih poremećaja
KR20200143739A (ko) 2012-12-20 2020-12-24 사렙타 쎄러퓨틱스 인코퍼레이티드 근위축증을 치료하기 위한 개선된 엑손 스키핑 조성물
WO2014113540A1 (fr) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. Cible intronique profonde pour la correction d'épissure sur le gène de l'amyotrophie spinale (sma)
EP2970964B8 (fr) 2013-03-14 2019-03-06 Sarepta Therapeutics, Inc. Compositions de sauts d'exon pour le traitement de la dystrophie musculaire
EA035882B1 (ru) 2013-03-14 2020-08-27 Сарепта Терапьютикс, Инк. Антисмысловые олигонуклеотиды, обеспечивающие пропуск экзонов, для лечения мышечной дистрофии
WO2014144978A2 (fr) 2013-03-15 2014-09-18 Sarepta Therapeutics, Inc. Compositions améliorées pour le traitement de la dystrophie musculaire
EP3015467A4 (fr) * 2013-05-24 2016-11-02 Ajinomoto Kk Procédé de fabrication de morpholino-oligonucléotide
TWI736514B (zh) 2013-09-05 2021-08-21 美商薩羅塔治療公司 酸性α葡萄糖苷酶之反義股誘導之外顯子２包含
US10517869B2 (en) 2013-12-24 2019-12-31 Sentiss Pharma Private Limited Topical brimonidine tartrate ophthalmic solution
MY193708A (en) * 2014-03-12 2022-10-26 Nippon Shinyaku Co Ltd Antisense nucleic acids
KR101661277B1 (ko) * 2014-03-17 2016-09-30 제주광어주식회사 한 개의 뉴크레오타이드 염기 변화를 통한 약독화 바이러스성 출혈패혈증 바이러스
WO2015175977A2 (fr) 2014-05-16 2015-11-19 Geller Bruce L Composés antisens antibactériens et procédés associés
EP3146047A4 (fr) 2014-05-19 2018-04-04 Oregon State University Composés antisens antibactériens et procédés
WO2016040748A1 (fr) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions et procédés de détection d'une protéine smn chez un patient et traitement d'un patient
WO2016108930A2 (fr) 2014-12-31 2016-07-07 Geller Bruce L Composés antibactériens antisens et procédés associés
JP2018509143A (ja) * 2015-02-27 2018-04-05 サレプタ セラピューティクス，インコーポレイテッド 酸性アルファ−グルコシダーゼにおけるアンチセンスに誘導されるエクソン２の組入れ
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
NZ737757A (en) * 2015-05-19 2023-07-28 Sarepta Therapeutics Inc Peptide oligonucleotide conjugates
US10849917B2 (en) 2015-06-01 2020-12-01 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type VII collagen
WO2016196897A1 (fr) 2015-06-04 2016-12-08 Sarepta Therapeutics, Inc. Procédés et composés pour le traitement de maladies et d'états pathologiques associés aux lymphocytes
MD3331891T2 (ro) * 2015-08-05 2022-04-30 Eisai R&D Man Co Ltd Procedeu de obţinere a unui oligomer de fosforodiamidat substanțial diastereomeric pur, a unui oligomer de fosforodiamidat obţinut printr-un astfel de procedeu și a unei compoziții farmaceutice care conţine un astfel de oligomer de fosforodiamidat
WO2017040271A1 (fr) * 2015-08-28 2017-03-09 Sarepta Therapeutics, Inc. Oligomères antisens modifiés pour l'inclusion d'exons dans l'atrophie musculaire spinale
KR101841241B1 (ko) * 2015-09-10 2018-03-22 한양대학교 산학협력단 피부 질환에 대한 예방 또는 치료효과를 갖는 펩티드 융합체 및 이를 유효성분으로 하는 약학 조성물
CN108699555A (zh) 2015-10-09 2018-10-23 萨勒普塔医疗公司 用于治疗杜兴肌营养不良和相关病症的组合物和方法
GB2545898B (en) * 2015-12-21 2019-10-09 Sutura Therapeutics Ltd Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides
AU2016379402B2 (en) 2015-12-23 2023-01-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
EP3394261A4 (fr) 2015-12-23 2019-11-27 Oregon State University Composés antibactériens antisens et procédés associés
US11060089B2 (en) * 2016-04-18 2021-07-13 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
MX2018013157A (es) * 2016-04-29 2019-05-23 Sarepta Therapeutics Inc Analogos de oligonucleotidos dirigidos a lmna humana.
AU2017270598B2 (en) * 2016-05-24 2022-12-01 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
KR20190024977A (ko) * 2016-06-30 2019-03-08 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머
PL3554554T3 (pl) * 2016-12-19 2022-12-19 Sarepta Therapeutics, Inc. Koniugaty oligomerów z pominięciem egzonu w dystrofii mięśniowej
KR20230110811A (ko) * 2016-12-19 2023-07-25 사렙타 쎄러퓨틱스 인코퍼레이티드 근육 이상증에 대한 엑손 스킵핑 올리고머 결합체
CA3047010A1 (fr) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Conjugues oligomeres de sauts d'exons pour la dystrophie musculaire
TW201919682A (zh) 2017-08-08 2019-06-01 西班牙商阿爾米雷爾有限公司 活化Ｎｒｆ２路徑的新穎化合物
EA201991450A1 (ru) * 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
EP3684933A4 (fr) * 2017-09-22 2021-06-23 The Regents of the University of Colorado, A Body Corporate Oligonucléotides thiomorpholino pour le traitement de la dystrophie musculaire
US20200248178A1 (en) 2017-09-28 2020-08-06 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
US20200254002A1 (en) 2017-09-28 2020-08-13 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
US20210145852A1 (en) 2017-09-28 2021-05-20 Sarepta Therapeutics, Inc. Combination Therapies for Treating Muscular Dystrophy
EP3697422A4 (fr) * 2017-10-17 2021-08-11 Sarepta Therapeutics, Inc. Peptides de pénétration cellulaire pour administration antisens
US11555189B2 (en) 2017-10-18 2023-01-17 Sarepta Therapeutics, Inc. Antisense oligomer compounds
EP3784248A4 (fr) * 2018-04-26 2022-08-10 Sarepta Therapeutics, Inc. Oligomères induisant le saut d'exon et conjugués d'oligomères pour la dystrophie musculaire
EP4219717A3 (fr) 2018-06-13 2023-12-20 Sarepta Therapeutics, Inc. Oligomères à saut d'exon pour la dystrophie musculaire
WO2019241385A2 (fr) * 2018-06-13 2019-12-19 Sarepta Therapeutics, Inc. Oligomères induisant un saut d'exon pour la dystrophie musculaire
TW202020153A (zh) 2018-07-27 2020-06-01 美商薩羅塔治療公司 用於肌肉萎縮症之外顯子跳躍寡聚物
TW202019442A (zh) * 2018-07-30 2020-06-01 美商薩羅塔治療公司 用於反義遞送之三聚合肽
GB201812980D0 (en) * 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
BR112021010982A2 (pt) * 2018-12-07 2021-08-31 Oxford University Innovation Limited Ligantes
JP2022511055A (ja) 2018-12-13 2022-01-28 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーに対するエクソンスキッピングオリゴマーコンジュゲート
GB201821269D0 (en) 2018-12-28 2019-02-13 Nippon Shinyaku Co Ltd Myostatin signal inhibitor
EP3955966A1 (fr) 2019-04-18 2022-02-23 Sarepta Therapeutics, Inc. Compositions pour le traitement de la dystrophie musculaire
CN110724180B (zh) * 2019-10-17 2021-08-20 山东大学 一种抑制新生血管生成的多肽及其应用
CN118109468A (zh) 2019-12-26 2024-05-31 日本新药株式会社 诱导外显子50的跳读的反义核酸
US20230203098A1 (en) 2020-02-22 2023-06-29 Jcr Pharmaceuticals Co., Ltd. Human transferrin receptor binding peptide
IL295967A (en) 2020-02-28 2022-10-01 Nippon Shinyaku Co Ltd Antisense nucleic acids for splicing on exon 51
BR112022016238A2 (pt) 2020-02-28 2022-10-11 Ionis Pharmaceuticals Inc Compostos e métodos para modular smn2
US20240024414A1 (en) * 2020-09-21 2024-01-25 Icahn School Of Medicine At Mount Sinai Archaea l30 proteins as universal influenza virus therapeutics
JP2024501800A (ja) 2020-12-23 2024-01-16 サレプタ セラピューティクス， インコーポレイテッド 筋ジストロフィーを治療するためのエクソンスキッピングオリゴヌクレオチドコンジュゲートを含む組成物
CA3211038A1 (fr) * 2021-02-12 2022-08-18 Oxford University Innovation Limited Conjugues peptidiques de penetration cellulaire et leurs procedes d'utilisation
WO2022232478A1 (fr) 2021-04-30 2022-11-03 Sarepta Therapeutics, Inc. Procédés de traitement pour dystrophie musculaire
TW202307208A (zh) 2021-06-23 2023-02-16 日商日本新藥股份有限公司 反義寡聚物之組合
TW202317147A (zh) 2021-07-08 2023-05-01 日商日本新藥股份有限公司 析出抑制劑
AU2022306820A1 (en) 2021-07-08 2024-01-04 Nippon Shinyaku Co., Ltd. Nephrotoxicity reducing agent
TW202308664A (zh) 2021-07-08 2023-03-01 日商日本新藥股份有限公司 腎毒性減輕劑
WO2023026994A1 (fr) 2021-08-21 2023-03-02 武田薬品工業株式会社 Conjugué peptide-médicament liant le récepteur de la transferrine humaine
EP4393959A1 (fr) 2021-08-24 2024-07-03 PeptiDream Inc. Conjugué anticorps-peptide se liant au récepteur de la transferrine humaine
AU2022358322A1 (en) 2021-09-30 2024-05-16 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (fr) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Oligomères morpholino pour le traitement de maladies liées à la protéine 22 de myéline périphérique
WO2023178230A1 (fr) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Conjugués d'oligomère morpholino phosphorodiamidate
WO2024064237A2 (fr) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Efficacité du saut d'exon médié par un oligonucléotide antisens dans le traitement de la dmd
US20240218365A1 (en) 2022-11-02 2024-07-04 Sarepta Therapeutics, Inc. Formulation of an antisense oligomer conjugate

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
JPH07501204A (ja) 1991-06-28 1995-02-09 マサチューセッツ インスティテュート オブ テクノロジー 局所的オリゴヌクレオチド療法
DE656950T1 (de) 1992-08-21 1996-03-14 Biogen Inc Tat-derivate transport polypeptide.
JPH0915828A (ja) 1995-07-03 1997-01-17 Fuji Photo Film Co Ltd 写真処理システム用ペーパーカッター
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
GB2341390B (en) 1997-05-21 2000-11-08 Univ Leland Stanford Junior Composition and method for enhancing transport across biological membranes
JP2002511885A (ja) * 1997-07-24 2002-04-16 ザ パーキン―エルマー コーポレーション 脂質膜を横切る輸送のための膜透過性構築物
DE19933492B4 (de) * 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
AU2002306500C1 (en) 2001-02-16 2006-09-28 Cellgate, Inc. Transporters comprising spaced arginine moieties
US20030224353A1 (en) 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
DK2351844T3 (da) 2003-04-29 2014-09-22 Sarepta Therapeutics Inc Præparater til forøgelse af transport- og antisense-effektivitet af nukleinsyreanalog i celler
KR101032853B1 (ko) 2003-08-05 2011-05-06 에이브이아이 바이오파마 인코포레이티드 웨스트 나일 바이러스 감염을 치료하기 위한 약학적 조성물
US20050171044A1 (en) 2003-12-24 2005-08-04 Stein David A. Oligonucleotide compound and method for treating nidovirus infections
EP1750775A2 (fr) * 2004-05-04 2007-02-14 Nastech Pharmaceutical Company Inc. Compositions et procedes pour l'amelioration de l'administration d'acides nucleiques dans des cellules et pour la modification de l'expression de genes cibles dans des cellules
US20050288246A1 (en) * 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
ATE498685T1 (de) 2004-06-28 2011-03-15 Univ Western Australia Antisense-oligonukleotide zur induktion von exon- skipping sowie verfahren zur verwendung davon
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US7838657B2 (en) 2004-12-03 2010-11-23 University Of Massachusetts Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
ES2852549T3 (es) 2005-02-09 2021-09-13 Sarepta Therapeutics Inc Composición antisentido para tratamiento de la atrofia muscular
SI2548560T1 (sl) 2005-06-23 2015-12-31 Isis Pharmaceuticals, Inc. Sestavki in postopki za moduliranje izrezovanja smn2
US8524676B2 (en) 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
AU2006287530A1 (en) 2005-09-08 2007-03-15 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating picornavirus infection
AU2007223776B2 (en) 2006-03-07 2014-05-22 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating Arenavirus infection
DK2024499T3 (da) 2006-05-10 2018-01-29 Sarepta Therapeutics Inc Oligonukleotidanaloger med kationiske intersubunit-koblinger
EP2049664B1 (fr) 2006-08-11 2011-09-14 Prosensa Technologies B.V. Oligonucléotides monocaténaires complémentaires des elements repetitifs pour le traitement de troubles génétiques associés a l'instabilité des répétitions de l'ADN
EP3034083B1 (fr) 2006-09-21 2020-12-09 University of Rochester Oligonucléotides antisens pour le traitement de la dystrophie myotonique
EP2070919B1 (fr) 2006-11-24 2012-10-10 Hykes Laboratories LLC Composé de spiroquinone et composition pharmaceutique
WO2009005783A1 (fr) * 2007-06-28 2009-01-08 Blanchette Rockefeller Neurosciences Institute Peptides, compositions et procédés pour réduire l'apoptose médiée par les bêta-amyloïdes
CA2691673A1 (fr) * 2007-06-29 2009-01-08 Avi Biopharma, Inc. Conjugues peptidiques specifiques d'un tissu et procedes
US20100016215A1 (en) * 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
CN101861318A (zh) 2007-11-15 2010-10-13 Avi生物制药公司 合成吗啉代低聚物的方法
EP2235175A4 (fr) * 2007-12-20 2012-04-25 Angiochem Inc Conjugués polypeptide-acide nucléique et leurs utilisations
US20110130346A1 (en) * 2008-05-30 2011-06-02 Isis Innovation Limited Peptide conjugates for delvery of biologically active compounds
CN102203253B (zh) * 2008-10-24 2016-04-06 萨雷普塔治疗公司 用于dmd的多外显子跳跃组合物
WO2010072228A1 (fr) * 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
US20120149757A1 (en) 2009-04-13 2012-06-14 Krainer Adrian R Compositions and methods for modulation of smn2 splicing
HUE046966T2 (hu) 2009-06-17 2020-04-28 Biogen Ma Inc Készítmények és módszerek az SMN2 splicing egy alanynál történõ modulálására
EP3023496B1 (fr) * 2010-05-13 2020-07-29 Sarepta Therapeutics, Inc. Composés modulants l'activité de signalement des interleukines 17 et 23

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO2012150960A1 *

Also Published As

Publication number Publication date
IL229227A0 (en) 2014-01-30
JP2018135396A (ja) 2018-08-30
CN107693797B (zh) 2021-05-11
IL273838A (en) 2020-05-31
KR102183273B1 (ko) 2020-11-27
CA2834128A1 (fr) 2012-11-08
JP6884250B2 (ja) 2021-06-09
CN103619356B (zh) 2017-09-12
IL273838B (en) 2022-09-01
JP6478632B2 (ja) 2019-03-06
AU2017206179A1 (en) 2017-08-03
JP2016185991A (ja) 2016-10-27
CA3092114A1 (fr) 2012-11-08
KR102339196B1 (ko) 2021-12-15
KR20190084351A (ko) 2019-07-16
CN107693797A (zh) 2018-02-16
IL229227B (en) 2020-07-30
AU2023203112A1 (en) 2023-06-08
JP2014515762A (ja) 2014-07-03
KR20140028058A (ko) 2014-03-07
AU2011367230A1 (en) 2013-12-05
AU2021202224A1 (en) 2021-05-06
JP2020111607A (ja) 2020-07-27
KR102229650B1 (ko) 2021-03-19
AU2011367230B2 (en) 2017-08-10
JP2024032974A (ja) 2024-03-12
CN103619356A (zh) 2014-03-05
AU2019204913A1 (en) 2019-07-25
JP2021113232A (ja) 2021-08-05
KR20210032545A (ko) 2021-03-24
WO2012150960A1 (fr) 2012-11-08

Similar Documents

Publication Publication Date Title
US11732259B2 (en) Peptide oligonucleotide conjugates
JP6884250B2 (ja) ペプチドオリゴヌクレオチドコンジュゲート
US20210139897A1 (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
AU2013202731B2 (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
NZ761522B2 (en) Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131202

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20181001

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517